[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 59 of about 59
1. Fermé C, Sebban C, Hennequin C, Diviné M, Lederlin P, Gabarre J, Ferrant A, Caillot D, Bordessoule D, Brice P, Moullet I, Berger F, Lepage E: Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'études des lymphomes de l'Adulte H89 trial. Blood; 2000 Apr 1;95(7):2246-52
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'études des lymphomes de l'Adulte H89 trial.
  • The treatment of advanced Hodgkin's disease (HD) with chemotherapy (CTx) alone or combined modality treatments has been controversial.
  • In 1989, we designed a randomized study to compare 2 cycles of CTx to (sub)total nodal irradiation (RTx) as consolidation treatments for patients with stage IIIB/IV HD in complete remission (CR) or good partial response after 6 cycles of CTx.
  • After induction treatment, 418 patients could be evaluated for the consolidation phase.
  • With a median follow-up of 48 months, the 5-year disease-free survival estimates were 80% for 8 cycles of MOPP/ABV, 82% for 6 cycles of MOPP/ABV plus RTx, 68% for 8 cycles of ABVPP, and 75% for 6 cycles of ABVPP plus RTx (P =.01).
  • The 5-year disease-free survival estimates did not differ between CTx and RTx, 74% and 79%, respectively (P =.07).
  • These results showed that RTx was not superior to CTx consolidation after doxorubicin-induced CR for patients with advanced HD.
  • Because of the uncertainty of obtaining a prolonged second remission for patients relapsing after CTx and RTx and the possible long-term effects of RTx, we prefer 8 cycles of CTx as standard treatment when a CR has been achieved after 6 cycles.
  • [MeSH-major] Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bleomycin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Humans. Mechlorethamine / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prospective Studies. Remission Induction. Survival Rate. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10733492.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; MOPP-ABV protocol
  •  go-up   go-down


2. Powell S, Dudek AZ: Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. Anticancer Res; 2009 Oct;29(10):4189-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.
  • BACKGROUND: High-dose interleukin-2 (HD IL-2) is known to produce durable responses in metastatic melanoma.
  • The purpose of this study was to evaluate the response of metastatic melanoma to treatment with HD IL-2.
  • PATIENTS AND METHODS: A retrospective analysis was performed on all adult patients with stage IV melanoma treated with HD IL-2 from January 2000 to October 2008 at the University of Minnesota.
  • HD IL-2 was given intravenously every 8 hours at 600,000 IU/kg for a maximum of 14 doses per course.
  • RESULTS: Fifteen patients with metastatic melanoma had been treated with HD IL-2.
  • There were 4 patients exhibiting some response, with 1 complete response (CR), 1 partial response (PR), 1 mixed response (MR) and 2 stable disease (SD).
  • Average time to disease progression (TTDP) was 5.67 months.
  • Two patients had complete resolution of brain lesions after HD IL-2 therapy.
  • One of these patients experienced CR and is disease free 34 months after stopping therapy.
  • The other patient experienced MR and is currently alive with disease, but without recurrence of brain lesions.
  • Twelve out of the 15 patients received 2 courses of therapy.
  • CONCLUSION: We propose further evaluation of HD IL-2 in patients with brain metastases because this patient population is typically considered ineligible for HD IL-2 therapy.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Interleukin-2 / administration & dosage. Melanoma / drug therapy. Melanoma / secondary
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Female. Humans. L-Lactate Dehydrogenase / metabolism. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Skin Neoplasms / drug therapy. Skin Neoplasms / secondary. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19846971.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Interleukin-2; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


3. Tarhini AA, Kirkwood JM, Gooding WE, Moschos S, Agarwala SS: A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma. Cancer; 2008 Oct 1;113(7):1632-40
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
  • BACKGROUND: Previous biochemotherapy regimens for metastatic melanoma have required attenuated dosages of interleukin 2 (IL-2) that may have compromised efficacy.
  • RESULTS: Thirty-eight patients with treatment-naive American Joint Committee on Cancer stage IV melanoma (8 patients with M1a disease, 6 patients with M1b disease, and 24 patients with M1c disease) were enrolled.
  • Responses were observed in patients with M1a disease and in patients with M1c disease.
  • Sixteen patients had stable disease (15 patients progressed).
  • CONCLUSIONS: The current results indicated that it is safe to administer HD IL-2 sequentially with temozolomide and that this combination has lower toxicity than previously used concurrent biochemotherapy regimens.
  • However, The ORR and the durability of responses with this combination did not exceed those of single-agent HD IL-2.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dacarbazine / analogs & derivatives. Interleukin-2 / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer. 2013 Feb 15;119(4):924
  • (PMID = 18720480.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA121973
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


Advertisement
4. Estes CS, Beauchamp CP, Clarke HD, Spangehl MJ: A two-stage retention débridement protocol for acute periprosthetic joint infections. Clin Orthop Relat Res; 2010 Aug;468(8):2029-38
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A two-stage retention débridement protocol for acute periprosthetic joint infections.
  • BACKGROUND: Due to the historically poor infection control rates with débridement and component retention for acute periprosthetic infections we developed a new approach for treating acute periprosthetic total joint infections: initial débridement with prosthesis retention and placement of antibiotic-impregnated cement beads followed by a second débridement within 7 days, at which time the beads are removed and new modular parts inserted.
  • QUESTIONS/PURPOSES: We determined the ability of this two-stage débridement to control infection.
  • Further research is required to analyze the individual contribution of débridement technique, the use of serial débridements, local depot antibiotics, and combination antibiotic therapy on short-term infection control rates and the long-term persistent control of periprosthetic infection.
  • LEVEL OF EVIDENCE: Level IV, therapeutic study.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Bacterial Infections / therapy. Debridement. Joint Prosthesis / adverse effects. Prosthesis-Related Infections / therapy. Surgical Wound Infection / therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Arthroplasty, Replacement, Hip. Arthroplasty, Replacement, Knee. Bone Cements. Combined Modality Therapy. Drug Delivery Systems. Female. Hip Prosthesis / adverse effects. Hip Prosthesis / microbiology. Humans. Knee Prosthesis / adverse effects. Knee Prosthesis / microbiology. Male. Middle Aged. Reoperation. Retrospective Studies. Treatment Failure

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 1999 Oct;81(10):1434-45 [10535593.001]
  • [Cites] Clin Orthop Relat Res. 2008 Nov;466(11):2628-33 [18781372.001]
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403):23-8 [12360003.001]
  • [Cites] Clin Orthop Relat Res. 2002 Nov;(404):125-31 [12439250.001]
  • [Cites] Clin Infect Dis. 2003 Apr 1;36(7):845-9 [12652384.001]
  • [Cites] J Arthroplasty. 2003 Oct;18(7 Suppl 1):22-6 [14560406.001]
  • [Cites] J Bone Joint Surg Am. 1974 Mar;56(2):273-84 [4452686.001]
  • [Cites] Clin Orthop Relat Res. 1976 Jun;(117):221-40 [776484.001]
  • [Cites] J Arthroplasty. 1990 Mar;5(1):35-9 [2319246.001]
  • [Cites] J Bone Joint Surg Am. 1990 Oct;72(9):1383-90 [2229118.001]
  • [Cites] Clin Orthop Relat Res. 1991 Dec;(273):105-12 [1959256.001]
  • [Cites] Clin Orthop Relat Res. 1991 Dec;(273):113-8 [1959257.001]
  • [Cites] Clin Orthop Relat Res. 1991 Dec;(273):98-104 [1959294.001]
  • [Cites] Clin Orthop Relat Res. 1992 May;(278):244-52 [1563160.001]
  • [Cites] J Bone Joint Surg Am. 1996 Apr;78(4):512-23 [8609130.001]
  • [Cites] Clin Orthop Relat Res. 1996 Oct;(331):146-50 [8895631.001]
  • [Cites] J Arthroplasty. 1996 Dec;11(8):931-8 [8986571.001]
  • [Cites] J Arthroplasty. 1997 Jun;12(4):426-33 [9195319.001]
  • [Cites] JAMA. 1998 May 20;279(19):1537-41 [9605897.001]
  • [Cites] J Bone Joint Surg Am. 1998 Sep;80(9):1306-13 [9759815.001]
  • [Cites] Am J Orthop (Belle Mead NJ). 1999 Mar;28(3):161-5 [10195839.001]
  • [Cites] J Bone Joint Surg Am. 1999 May;81(5):672-83 [10360695.001]
  • [Cites] Arthroscopy. 2005 Mar;21(3):303-6 [15756183.001]
  • [Cites] J Bone Joint Surg Am. 2005 Jul;87(7):1415-22 [15995106.001]
  • [Cites] Clin Microbiol Infect. 2006 May;12(5):433-9 [16643519.001]
  • [Cites] Clin Orthop Relat Res. 2007 Aug;461:130-5 [17438469.001]
  • [Cites] J Bone Joint Surg Am. 2008 Aug;90(8):1637-43 [18676892.001]
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403):8-15 [12360001.001]
  • (PMID = 20224958.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bone Cements
  • [Other-IDs] NLM/ PMC2895840
  •  go-up   go-down


5. Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, Morris RT, DeGeest K, Lee R, Montag A: A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol; 2009 Mar;112(3):543-52
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: After surgical debulking and volume-directed irradiation of the pelvis/para-aortic lymph nodes, treatment was randomized to compare recurrence-free survival (RFS) and toxicity between two chemotherapy regimens for the treatment of women with advanced stage endometrial carcinoma.
  • METHODS: Treatment was randomized between 6 cycles of cisplatin [C] (50 mg/m(2)) and doxorubicin [D] (45 mg/m(2)) with or without paclitaxel [P] (160 mg/m(2)).
  • RESULTS: Of 659 patients enrolled following surgery, 552 eligible patients were randomized to chemotherapy after irradiation.
  • Accrual closed to Stage IV patients in June, 2003.
  • Approximately 80% completed six cycles of chemotherapy.
  • The hazard of recurrence or death relative to the CD arm stratified by stage is 0.90 (95% CI is 0.69 to 1.17, p=0.21, one-tail).
  • However, in subgroup analysis, CDP was associated with a 50% reduction in the risk of recurrence or death among patients with gross residual disease (95% CI: 0.26 to 0.92).
  • Stage, residual disease, histology/grade, positive para-aortic node and cytology, pelvic metastases and age were significantly associated with RFS.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19108877.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA101165-04; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / U10 CA027469-22; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS102171; NLM/ PMC4459781
  •  go-up   go-down


6. Huang HQ, Jiang WQ, Wang W, Xu GC, Zhang L, He YJ, Sun XF, Zhou ZM, Liu DG, Xu RH, Lin TY, Teng XY, Liu MZ, Su YS, Li YH, Lin XB, Guan ZZ: [Clinical results of 295 patients with Hodgkin's disease treated by chemotherapy-predominant comprehensive modality]. Ai Zheng; 2002 Dec;21(12):1345-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical results of 295 patients with Hodgkin's disease treated by chemotherapy-predominant comprehensive modality].
  • BACKGROUND & OBJECTIVE: Hodgkin's disease (HD) is a chemo- and radio-sensitive hematologic malignancy.
  • At present, improvement of cure rate, reduction of long-term toxicity, and maintenance of good quality of life are the major issues in the treatment of HD.
  • METHODS: The results of 295 patients with histology-proven HD from 1970 to 2000, especially from 1980 to 2000 were analyzed.
  • RESULTS: A total of 295 HD patients were treated by chemotherapy-predominant comprehensive modality.
  • The 5, 10, and 20 years overall survival for 295 HD patients were 63.5%, 55.8%, and 47.1%, respectively, with median survival time of 172.3 months (28-351.9 months) at the median follow-up time of 42.9 months (17-351.9 months).
  • The 5, 10, and 20 years overall survival and disease-free survival were 79.6%, 74.5%, and 66.8% as well as 74.5%, 69.4%, and 69.4% respectively for the patients treated with regular chemotherapy and radiotherapy from 1980 to 2000.
  • Multivariate analysis demonstrated that age over 45-year-old, B symptoms and stage III/IV were the main prognostic factors (P = 0.000, P = 0.035, and P = 0.047) in this clinical study.
  • The prognosis of the patients with stage I/II and nodular sclerosis was better in comparison to stages III/IV and other histologic subtypes.
  • CONCLUSIONS: Chemotherapy-predominant combined with involved fields irradiation play an important role in HD treatment with promising long term survival and lower late toxicities.
  • [MeSH-major] Hodgkin Disease / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Clinical Trials as Topic. Combined Modality Therapy. Drug Therapy. Female. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12520745.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Di Nicola M, Carlo-Stella C, Mariotti J, Devizzi L, Massimino M, Cabras A, Magni M, Matteucci P, Guidetti A, Gandola L, Gianni AM: High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. Br J Haematol; 2004 Sep;126(6):815-20
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults.
  • A very short, intensive paediatric chemotherapy programme was tested in a consecutive monoinstitutional group of 22 adult Burkitt's lymphoma (BL) patients.
  • After a 5-week induction phase of weekly infusions consisting of vincristine, cyclophosphamide, doxorubicin, high-dose (HD) methotrexate (MTX) plus leukovorin rescue, and intrathecal MTX or cytarabine (ARA-C), a consolidation phase including HD ARA-C plus cisplatin was given.
  • Responding patients achieving less than complete response (CR) after completion of the initial induction phase, were promptly shifted to a high-dose, stem cell supported sequential chemotherapy schema (R-HDS).
  • PATIENT CHARACTERISTICS: median age, 35.5 (range 18-76) years; Ann Arbor stage I-II/III-IV, 11/11; bulky disease, 15 patients; LDH > or = 460 U/l, 11 patients.
  • The median duration of the chemotherapy programme was 62 d (range, 43-94 d).
  • Seventeen patients achieved a CR (77%), one patient died of progressive disease and four partial responders following induction were converted to CR following R-HDS.
  • Of 17 patients in CR, one died of infectious toxicity while in CR, and one relapsed at 30 months and died of progressive disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Leucovorin / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Retrospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15352985.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


8. Takenaka T, Mikuni C, Miura A, Sasaki T, Suzuki H, Hotta T, Hirano M, Fukuhara S, Sugiyama H, Nasu K, Dohi H, Kozuru M, Tomonaga M, Tajima K, Niimi M, Fukuda H, Mukai K, Shimoyama M: Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group. Jpn J Clin Oncol; 2000 Mar;30(3):146-52
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group.
  • BACKGROUND: The main form of cytotoxic treatment for advanced Hodgkin's disease (HD) is conventional dose multiagents chemotherapy.
  • As HD is not common in Japan, we conducted a phase II study of the commonly used combination chemotherapy (CCT) regimen established in the West for Japanese patients with advanced HD to confirm the efficacy and safety.
  • METHOD: Between October 1989 and February 1993, a multicenter phase II study of alternating CCT C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, vinblastine, bleomycin, dacarbazine) to evaluate its clinical usefulness for clinical stage (cS) II-IV HD was conducted by the Lymphoma Study Group of the Japan Clinical Oncology Group.
  • For 40 cS II and 27 cS III/IV patients the response rate was 95.0% with 90.0% CR and 88.9% with 74.1% CR, respectively.
  • Those of cS II and cS III/IV were 92.5 and 73.1%, respectively.
  • There was no significant difference between cS II and cS III/IV (p = 0.1025).
  • Those of cS II and cS III/IV were 77.5 and 65.7%, respectively.
  • There was no significant difference between cS II and cS III/IV (p = 0.2483).
  • There was GPT elevation in 4.5%, nausea/vomiting in 11.9% and CNS in 1.5% of patients, but there was no treatment-related death.
  • CONCLUSION: The C-MOPP/ABVd regimen for Japanese patients with advanced HD is considered to be one of the effective CCTs according to the results of the present phase II study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Prednisolone / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Survival Rate. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10798542.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; ABVD protocol; CMOPP protocol
  •  go-up   go-down


9. Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E: Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Cancer; 2000 May 1;88(9):2142-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
  • BACKGROUND: Combination chemotherapy, including hybrid regimens, is the standard treatment for patients with advanced Hodgkin disease (HD).
  • Cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) is a hybrid chemotherapy in which cyclophosphamide is substituted for mechlorethamine, an agent that has been implicated as the cause of secondary malignancies.
  • METHODS: Seventy-three patients (37 males and 36 females; median age, 35 years) diagnosed with Stage III or IV HD or Stage II with bulky disease, B-symptoms, elevated erythrocyte sedimentation rate, or hilar adenopathy were treated with 8 courses of C-MOPP/ABV at a single institution during a 6-year period.
  • Radiotherapy (RT) was administered when bulky disease or residual masses were present.
  • Endpoints of the study were response to therapy, failure free survival (FFS), overall survival (OS), and toxicity.
  • After chemotherapy, 57 patients (78%) reached CR.
  • Two patients died during treatment because of sepsis and four due to disease progression.
  • CONCLUSIONS: C-MOPP/ABV induces CR with acceptable toxicity in a high proportion of advanced HD patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Bleomycin / administration & dosage. Bleomycin / adverse effects. Confidence Intervals. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Radiotherapy, Adjuvant. Remission Induction. Survival Rate. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10813727.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


10. Fermé C, Mounier N, Diviné M, Brice P, Stamatoullas A, Reman O, Voillat L, Jaubert J, Lederlin P, Colin P, Berger F, Salles G: Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol; 2002 Jan 15;20(2):467-75
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.
  • PURPOSE: To evaluate prospectively the feasibility and efficacy of early intensive therapy, including intensified cytoreductive chemotherapy (CT) and high-dose CT (HDCT) followed by autologous stem-cell transplantation (ASCT), in patients with advanced Hodgkin's disease (HD) who failed to respond completely or relapsed after initial treatment.
  • PATIENTS AND METHODS: Among 533 eligible patients with newly diagnosed stage IIIB-IV HD enrolled in the H89 trial, all 157 patients with induction failure (IF) (n = 67), partial response (PR) of less than 75% (n = 22), or relapse (n = 68) were included in this study.
  • Planned salvage therapy included mitoguazone, ifosfamide, vinorelbine, and etoposide monthly for two to three cycles followed by high-dose carmustine, etoposide, cytarabine, and melphalan with ASCT.
  • Multivariate analysis using time-dependent Cox model indicated that B symptoms at progression, salvage without HDCT, and chemoresistant disease before HDCT were significantly associated with shorter overall survival.
  • CONCLUSION: Early intensive therapy improves the outcomes of patients with advanced HD who failed to respond completely to initial treatment and those who relapsed with adverse prognostic factors.
  • However, for patients with IF and chemoresistant disease, this approach remains unsatisfactory.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Hodgkin Disease / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Aged. Carmustine / administration & dosage. Cytarabine / administration & dosage. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Melphalan / administration & dosage. Middle Aged. Mitoguazone / administration & dosage. Recurrence. Salvage Therapy. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11786576.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; OD5Q0L447W / Mitoguazone; Q41OR9510P / Melphalan; Q6C979R91Y / vinorelbine; U68WG3173Y / Carmustine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


11. Möbus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimmig R, Ostermann H, Hinke A, Ledermann JA, AGO-Ovar/AIO, EBMT: Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol; 2007 Sep 20;25(27):4187-93
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
  • PURPOSE: Although ovarian cancer is one of the most chemotherapy-sensitive solid tumors, cure after radical surgery and chemotherapy is uncommon.
  • A randomized trial comparing high-dose sequential chemotherapy with peripheral blood stem cell (PBSC) support with platinum-based combination chemotherapy was conducted to investigate whether dose-intensification improves outcome.
  • PATIENTS AND METHODS: One hundred forty-nine patients with untreated ovarian cancer were randomly assigned after debulking surgery to receive standard combination chemotherapy or sequential high-dose (HD) treatment with two cycles of cyclophosphamide and paclitaxel followed by three cycles of HD carboplatin and paclitaxel with PBSC support.
  • HD melphalan was added to the final cycle.
  • The median age was 50 years (range, 20 to 65 years) and International Federation of Gynecology and Obstetrics stage was IIb/IIc in 4%, III in 78%, and IV in 17%.
  • RESULTS: Seventy-six percent of patients received all five cycles in the HD arm and the main toxicities were neuro-/ototoxicity, gastrointestinal toxicity, and infection and one death from hemorrhagic shock.
  • After a median follow-up of 38 months, the progression-free survival was 20.5 months in the standard arm and 29.6 months in the HD arm (hazard ratio [HR], 0.84; 95% CI, 0.56 to 1.26; P, .40).
  • Median overall survival (OS) was 62.8 months in the standard arm and 54.4 months in the HD arm (HR, 1.17; 95% CI, 0.71 to 1.94; P, .54).
  • CONCLUSION: This is the first randomized trial comparing sequential HD versus standard dose chemotherapy in first-line treatment of patients with advanced ovarian cancer.
  • We observed no statistically significant difference in progression-free survival or OS and conclude that HD chemotherapy does not appear to be superior to conventional dose chemotherapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cyclophosphamide / administration & dosage. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Paclitaxel / administration & dosage. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Melphalan / administration & dosage. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Sep 20;25(27):4157-8 [17698802.001]
  • (PMID = 17698804.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; Q41OR9510P / Melphalan
  •  go-up   go-down


12. Levine AM, Li P, Cheung T, Tulpule A, Von Roenn J, Nathwani BN, Ratner L: Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr; 2000 Aug 15;24(5):444-50
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149).
  • To ascertain the results of standard ABVD chemotherapy (doxorubicin, bleomycin, vinblastine, dacarbazine) in HIV-infected patients with newly diagnosed Hodgkin's disease (HD), a nonrandomized, prospective, multiinstitutional clinical trial was conducted by the AIDS Clinical Trials Group (ACTG), in HIV-infected patients with Hodgkin's disease.
  • Antiretroviral therapy was not used.
  • The median CD4 count was 113 cells/mm3, and 29% had a history of a clinical AIDS-defining condition before diagnosis of HD.
  • Stage IV HD was present in 67%, with bone marrow involvement in 12 (57%).
  • Nodular sclerosis HD was present in 38%, with mixed cellular disease in 31%.
  • Results of this study suggest that alternative treatment strategies should be explored, including use of chemotherapy together with antiretroviral therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / therapeutic use. HIV Infections / complications. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. CD4 Lymphocyte Count. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Drug Therapy, Combination. Female. Humans. Karnofsky Performance Status. Male. Middle Aged. Prospective Studies. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11035615.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Grant] United States / PHS HHS / / N01-A1-62540
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


13. Brice P, Colin P, Berger F, de Kerviler E, Diviné M, Bouaffia F, Kerneis Y, Blanc M, Lepage E, Fermé C, Groupe d'Etude des Lymphomes de l'Adulte: Advanced Hodgkin disease with large mediastinal involvement can be treated with eight cycles of chemotherapy alone after a major response to six cycles of chemotherapy: a study of 82 patients from the Groupes d'Etudes des Lymphomes de l'Adulte H89 trial. Cancer; 2001 Aug 1;92(3):453-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced Hodgkin disease with large mediastinal involvement can be treated with eight cycles of chemotherapy alone after a major response to six cycles of chemotherapy: a study of 82 patients from the Groupes d'Etudes des Lymphomes de l'Adulte H89 trial.
  • BACKGROUND: The prognostic impact of large mediastinal involvement (mediastinum/thorax [M/T] ratio > 0.33) in advanced Hodgkin disease (HD) and the optimal treatment with chemotherapy or combined treatment remains controversial.
  • METHODS: Among 533 assessable patients with Ann Arbor Stage IIIB/IV HD included in the H89 trial, 82 had large mediastinal mass defined on chest X-ray.
  • All patients received induction with six cycles of chemotherapy (mechlorethamine, vincristine, procarbazine, prednisone-doxorubicin, bleomycin, vinblastine or doxorubicin, vinblastine, bleomycin, procarbazine, prednisone); then complete and good partial responders were randomized between two consolidation treatments: 2 cycles of the same chemotherapy or (sub)total lymph node irradiation.
  • A large mediastinal mass was associated with supradiaphragmatic disease, younger age, histologic nodular sclerosis, and different sex ratio compared with other H89 trial patients.
  • Although the major response rate to induction chemotherapy (after 6 cycles) was lower for patients with large mediastinal mass (78% vs. 86%), the 5-year overall survival rate (80% vs. 79%) and event free survival rate (59% vs. 61%) were similar (P = 0.64 and 0.3, respectively).
  • Analysis of progression showed that 68% (21 of 31) of failures occurred early during treatment and involved the mediastinum in 86% of the cases.
  • CONCLUSIONS: For patients with large mediastinal mass and advanced HD who achieved a major response of at least 75% after 6 cycles of chemotherapy, a consolidation radiation therapy can be replaced by 2 additional cycles of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Doxorubicin / therapeutic use. Hodgkin Disease / drug therapy. Mechlorethamine / therapeutic use. Mediastinal Diseases / drug therapy. Prednisone / therapeutic use. Procarbazine / therapeutic use. Vinblastine / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Male. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11505388.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; MOPP-ABV protocol
  •  go-up   go-down


14. Brenot-Rossi I, Bouabdallah R, Di Stefano D, Bardou VJ, Stoppa AM, Camerlo J, Sauvan R, Gastaut JA, Pasquier J: Hodgkin's disease: prognostic role of gallium scintigraphy after chemotherapy. Eur J Nucl Med; 2001 Oct;28(10):1482-8
Hazardous Substances Data Bank. GALLIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease: prognostic role of gallium scintigraphy after chemotherapy.
  • Evaluation of the response to therapy is important for optimal selection of treatment strategy in patients with Hodgkin's disease (HD).
  • Refractory disease requires intensive high-dose chemotherapy, whereas unnecessary treatment should be avoided in patients in complete remission.
  • The purpose of this study was to evaluate the contribution of gallium-67 scintigraphy in predicting the clinical outcome in patients with HD and mediastinal involvement on the basis of scan results at the end of chemotherapy.
  • Seventy-four patients with HD and mediastinal involvement were retrospectively investigated with 67Ga scintigraphy 72 h after injection of 220 MBq 67Ga citrate (planar and single-photon emission tomographic studies) following the completion of chemotherapy.
  • At the same time, they all underwent computed tomography (CT).
  • The disease status was newly diagnosed disease in 64 of the patients and relapse in 10.
  • Forty-one patients had stage I or II disease and 33 patients had stage III or IV disease.
  • Twenty-two patients had bulky disease on initial diagnosis.
  • At the end of chemotherapy, all 74 patients showed regression of the mass by more than 50% (50%-100%) on CT.
  • Patients were divided into two groups according to the positivity or negativity of the gallium scan after chemotherapy: 61 patients had negative and 13 patients had positive gallium scans.
  • In the gallium-positive group, 84.6% of the patients had recurrent disease and 61.5% were alive after intensive chemotherapy.
  • Disease-free survival differed significantly between patients with positive and patients with negative gallium scans at the end of chemotherapy (P<0.0001).
  • It is concluded that even if gallium scan is performed at the end of chemotherapy, it can predict outcome.
  • Alternative therapy may be required on the basis of gallium scan results obtained after treatment.
  • [MeSH-major] Citrates. Gallium. Hodgkin Disease / mortality. Hodgkin Disease / radionuclide imaging. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11685490.001).
  • [ISSN] 0340-6997
  • [Journal-full-title] European journal of nuclear medicine
  • [ISO-abbreviation] Eur J Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Citrates; 0 / Radiopharmaceuticals; 27905-02-8 / gallium citrate; CH46OC8YV4 / Gallium
  •  go-up   go-down


15. Kovács AF, Mose S, Böttcher HD, Bitter K: Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer. Strahlenther Onkol; 2005 Jan;181(1):26-34
Hazardous Substances Data Bank. SODIUM THIOSULFATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer.
  • BACKGROUND: To examine the feasibility and efficacy of weekly docetaxel with concurrent radiation as postoperative treatment in a multimodality approach to oral and oropharyngeal cancer.
  • PATIENTS AND METHODS: 94 patients (Table 1) with primary resectable squamous cell carcinoma of the oral cavity and oropharynx (UICC stage I 14%, II 15%, III 18%, IV 53%; Table 2) were treated with a multimodality therapy program consisting of neoadjuvant intra-arterial high-dose chemotherapy (cisplatin 150 mg/m(2) with parallel systemic sodium thiosulfate 9 g/m(2) for neutralization), followed by surgery of the primary and neck, and postoperative concurrent radiation and chemotherapy with weekly docetaxel (20-30 mg/m(2); Table 3).
  • RESULTS: At a median follow-up of 4 years, the 5-year survival rate for all 94 patients was 80%, and disease-free survival was 73% (Figures 1 and 2).
  • Among patients with advanced disease (stage III and IV), survival was 83 and 59%, respectively (Figure 4).
  • CONCLUSIONS: Concurrent radiation and chemotherapy with weekly docetaxel is a feasible postoperative treatment in a multimodality approach to oral and oropharyngeal cancer, resulting in high overall and disease-free survival.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy. Radiotherapy, Adjuvant. Taxoids / administration & dosage
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Feasibility Studies. Female. Follow-Up Studies. Head / pathology. Humans. Infusions, Intravenous. Injections, Intra-Arterial. Male. Middle Aged. Neck / pathology. Neck Dissection. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Care. Radiotherapy Dosage. Survival Analysis. Thiosulfates / administration & dosage. Thiosulfates / therapeutic use. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660190.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 0 / Thiosulfates; 15H5577CQD / docetaxel; HX1032V43M / sodium thiosulfate; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Reichle A, Bolder U, Bataille F, Messmann H, Wagner H, Zaiss M, Wild P, Hofstädter F, Andreesen R, Jauch KW: A multimodal treatment approach including high-dose chemotherapy in very advanced gastric cancer: evidence for control of metastatic disease. Bone Marrow Transplant; 2003 Oct;32(7):665-71
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multimodal treatment approach including high-dose chemotherapy in very advanced gastric cancer: evidence for control of metastatic disease.
  • The present multimodal treatment approach was designed to achieve prolonged tumor control in advanced gastric cancer.
  • A total of 26 patients with stage IV gastric cancer (metastatic disease n=25), ECOG performance status 0-3 and laparoscopically evaluated peritoneal status received a modified EAP schedule to prove chemosensitivity and to mobilize autologous peripheral blood stem cells (aPBSC).
  • Patients without progressive disease proceeded to tandem high-dose chemotherapy (HD-CT) and aPBSCT.
  • Patients with >50% reduction of the target lesion received a second cycle of HD-CT.
  • Of 26 patients, 20(77%) achieved partial remission after dose-intensive chemotherapy: local R0 resection was achieved in 12 out of 14 patients selected for surgery (46% of all patients).
  • The combined treatment approach is tolerable and feasible in advanced disease and opens a therapeutic window for a significant proportion of patients, even in cases with histologically proven peritoneal carcinomatosis.
  • [MeSH-major] Combined Modality Therapy / methods. Neoplasm Metastasis / prevention & control. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / toxicity. Female. Gastrectomy. Humans. Length of Stay. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation / adverse effects. Peripheral Blood Stem Cell Transplantation / methods. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 13130313.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Leung AM, Vu HN, Nguyen KA, Thacker LR, Bear HD: Effects of surgical excision on survival of patients with stage IV breast cancer. J Surg Res; 2010 Jun 1;161(1):83-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of surgical excision on survival of patients with stage IV breast cancer.
  • BACKGROUND: Non-palliative resection of the primary tumor in stage IV breast cancer is controversial.
  • Our aim was to determine whether surgery improves survival in stage IV patients.
  • METHODS: We reviewed records of all stage IV breast cancer patients (1990-2000) at our institution.
  • Data collection included demographics, metastasis sites, treatment, and survival.
  • Survival was compared between metastasis type, hormonal therapy versus no hormonal therapy, chemotherapy versus no chemotherapy, radiation versus no radiation, and surgery versus no surgery.
  • To ascertain local therapy effects while accounting for chemotherapy, we analyzed survival among chemotherapy alone versus chemotherapy with radiation versus chemotherapy with surgery.
  • Eighty (51%) received hormonal therapy while 77 (49%) did not.
  • Eighty-four (54%) received chemotherapy with a 25-mo median survival versus 8 mo for 73 (46%) not receiving chemotherapy, Wilcoxon (P < 0.0001), and log-rank (P = 0.02).
  • Among patients receiving chemotherapy, 37 with chemotherapy alone had a 21-mo median survival versus 40 mo for the 14 with chemotherapy and radiation and 22 mo for the 33 with chemotherapy and surgery.
  • Multivariate analysis determined chemotherapy as the only factor associated with improved survival (P = 0.02).
  • CONCLUSION: Our data, when standardized for chemotherapy, suggests loco-regional therapy does not improve survival.
  • [MeSH-major] Breast / surgery. Breast Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Bone Neoplasms / mortality. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Female. Humans. Kaplan-Meier Estimate. Linear Models. Middle Aged. Neoplasm Metastasis. Radiotherapy, Adjuvant. Retrospective Studies. Virginia / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19375721.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


18. Lester EP, Petroni GR, Barcos M, Johnson JL, Millard FE, Cooper MR, Omura GA, Frei E 3rd, Peterson BA: Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856. Cancer Invest; 2001;19(5):447-58
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856.
  • Successful treatment of advanced-stage Hodgkin's disease (HD) may critically depend on dose intensity.
  • Because mechlorethamine, Oncovin, procarbazine, and prednisone (MOPP), and Adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) are not suitable for major dose escalation, we evaluated the activity and toxicity of combined cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) in advanced HD, here used at conventional dose intensity, as a preparatory study prior to using this regimen at higher dose intensity.
  • All had advanced HD with no prior chemotherapy with 46% stage IV, 63% with B symptoms, and 57% with bulky disease (> 5 cm).
  • CHOPE, at conventional dose intensity as used here, is an effective first-line regimen for the treatment of advanced-stage HD and may warrant evaluation using higher doses of cyclophosphamide and etoposide with granulocyte colony stimulating factor (G-CSF) support.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11458812.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / CA16450; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA47545; United States / NCI NIH HHS / CA / CA47555
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; EPOCH protocol
  •  go-up   go-down


19. Ferme C, Mounier N, Diviné M, Groupe d'Etudes des Lymphomes de l'Adulte: Current clinical trials for the treatment of adult advanced-stage Hodgkin's disease: GELA experiences. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol; 2002;13 Suppl 1:96-7
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current clinical trials for the treatment of adult advanced-stage Hodgkin's disease: GELA experiences. Groupe d'Etudes des Lymphomes de l'Adulte.
  • BACKGROUND: The optimal treatment for patients with advanced Hodgkin's disease (HD) responding to initial chemotherapy (CT) and an intensive salvage therapy for those who fail to respond completely after initial treatment were evaluated prospectively.
  • PATIENTS AND METHODS: The Groupe d'etudes des Lymphomes de l'Adulte H89 trial compared two cycles of CT with (sub)total nodal irradiation (RT) as consolidation treatments for patients with stage IIIB/IV HD with a complete response (CR) or good partial response (PR) after six cycles of CT.
  • Early salvage therapy, including intensified cytoreductive CT and high-dose CT with autologous stem-cell transplantation, was integrated into the trial for patients who had failed to respond completely or relapsed after initial treatment.
  • RESULTS: The study does not demonstrate any advantage of RT over CT as consolidation treatment at the time of CT-induced CR or good PR.
  • Early intensive therapy improves the outcomes of patients with PR and those who relapsed with unfavourable factors.
  • This strategy remains unsatisfactory for patients with primary refractory disease and chemoresistant disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12078912.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 3
  •  go-up   go-down


20. Coleman M, Kaufmann T, Nisce LZ, Leonard JP: Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation. Int J Radiat Oncol Biol Phys; 2000 Mar 15;46(5):1235-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation.
  • PURPOSE: At the New York Presbyterian Hospital-Cornell Medical Center, patients with unequivocal clinical stage I and IIA Hodgkin's disease (HD) have been treated with mantle, splenic, and extended field radiation therapy (EFRT) (without surgical staging).
  • METHODS AND MATERIALS: During the period 1971 to 1994, 94 patients with clinically staged HD, with favorable prognostic factors, were retrospectively reviewed.
  • Patients with pathological or equivocal staging, "B" symptoms, bulk disease, history of previous chemotherapy, and/or Stage III or IV disease were excluded from our analysis.
  • There were 27 Stage IA and 67 Stage IIA patients.
  • The median time to relapse was 38 months; mean time 42. 3 months.
  • All patients are alive, well and free of disease, including nine who received subsequent chemotherapy and one who underwent autotransplantation.
  • CONCLUSIONS: Careful clinical staging of early, asymptomatic HD patients treated with mantle, splenic, and EFRT may obviate the need for exploratory laparotomy.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Spleen
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Recurrence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10725636.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 07968
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


21. Perez EA, Geoffroy FJ, Hillman S, Johnson EA, Farr GH Jr, Tazelarr HD, Hatfield AK, Krook JE, Maillard JA, Levitt R, Marks RS: Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer. Lung Cancer; 2004 Jun;44(3):347-53
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer.
  • BACKGROUND: This study evaluated the activity and tolerance for the combination of oral etoposide and paclitaxel as first-line therapy for patients with extensive SCLC.
  • A cycle of chemotherapy consisted of oral etoposide administered as 50 mg BID on days 1 through 10 and paclitaxel administered as 150 mg/m(2) IV (3 h infusion) along with the first dose of etoposide on day 10.
  • Patients were assessed for response to therapy (regression, stable disease, progression), survival, time to disease progression, and toxicity.
  • Among the 55 patients, there were six with complete regression of disease, 18 with partial regression, 11 with regression, five with stable disease, and 15 with progressive disease, yielding an overall response rate of 63.6% (95% confidence interval, 50.0-76.0%).
  • The median time to disease progression was 5.8 months.
  • The combination of oral etoposide and paclitaxel demonstrated significant efficacy as first-line therapy for extensive SCLC, with an overall response rate of 63.6% for 55 evaluable patients.
  • In addition, the treatment was well tolerated with no unexpected toxicities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Small Cell / drug therapy. Etoposide / administration & dosage. Lung Neoplasms / drug therapy. Paclitaxel / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Drug Synergism. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15140548.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35272; United States / NCI NIH HHS / CA / CA-35415; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / CA-63849; United States / NCI NIH HHS / CA / CA35269
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


22. Schaefer PL, Marks RS, Mahoney MR, Sloan JA, Bauman MD, Tazelaar HD, Kugler JW, Mailliard JA, Ebbert LP, Wiesenfeld M: Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers. Am J Clin Oncol; 2003 Jun;26(3):236-40
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
  • A randomized two-stage, phase II study was conducted to assess the antitumor activity of two different schedules of topotecan in the treatment of extensive-stage small-cell lung cancer (SCLC) in chemotherapy-naive patients.
  • Toxicity was predominantly hematologic with 92% (55/60) having greater than or equal to grade III neutropenia and 58% (35/60) reporting greater than or equal to grade III leukopenia for both IV schedules.
  • Nonhematologic toxicity was very mild, with only 10% (6/60) patients experiencing grade IV toxicities.
  • Median times to progression for the daily and continuous-infusion schedules are 5 months (90% CI: 4.4-7.2) and 2 months (90% CI: 1.1-2.1), respectively.
  • Fifty percent (30/60) of patients received second-line therapy with etoposide and cisplatin.
  • Forty-three percent (13/30) of patients who received second-line therapy achieved a confirmed response.
  • Topotecan showed significant activity in the treatment of extensive stage SCLC when administered as a brief daily IV repeated every 3 weeks.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy. Topotecan / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12796591.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / CA-63849; United States / NCI NIH HHS / CA / CA60276
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; 7M7YKX2N15 / Topotecan; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Molina JR, Jett JR, Foster N, Lair BS, Carroll TJ, Tazelaar HD, Hillman S, Mailliard JA, Bernath AM Jr, Nikcevich D: Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer. Am J Clin Oncol; 2006 Jun;29(3):246-51
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer.
  • OBJECTIVE: To determine the efficacy and toxicity of oral topotecan and paclitaxel in untreated patients with extensive stage small cell lung cancer (SCLC).
  • PATIENTS AND METHODS: Thirty-eight patients received 1.75 mg/m2 of oral topotecan days 1 to 5 and 175 mg/m2 paclitaxel IV over 3 hours on day 5 (after topotecan) every 4 weeks for 6 cycles.
  • Subcutaneous G-CSF at a dose of 5 microg/kg was then given 24 to 48 hours after the last dose of chemotherapy and daily for 10 days.
  • A median of 5 treatment cycles was given, with a range of 1 to 7 cycles.
  • Seventeen (45%) patients received at least 6 cycles of treatment.
  • Two grade 5 treatment-related evens were seen.
  • The median time to progression was 5.0 months (95% CI: 3.8-6.6 months), with a 1-year progression-free rate of 5.8% (95% CI: 1.5-22.2%) and a 2-year progression-free rate of 2.9% (95% CI: 0.4-19.9%).
  • CONCLUSION: This regimen has shown similar antitumor activity to that achieved with standard therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Disease Progression. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Infusions, Intravenous. Injections, Subcutaneous. Male. Middle Aged. Paclitaxel / administration & dosage. Survival Analysis. Topotecan / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755177.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35431; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-35629; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-CA-63849
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7M7YKX2N15 / Topotecan; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


24. Balwierz W, Moryl-Bujakowska A, Depowska T, Klekawka T, Rokicka-Milewska R, Sopylo B, Kolakowska-Mrozowska B, Chybicka A, Boguslawska-Jaworska J, Pisarek J, Ras M, Sonta-Jakimczyk D, Janik-Moszant A, Kolecki P, Kaczmarek-Kanold M, Kowalczyk J, Odoj T, Matysiak M, Newecka-Samol T, Balcerska A, Adamkiewicz-Drozynska E, Wysocki M, Kurylak A: [Treatment regimen for children and adolescents with Hodgkin's disease designed to decrease late complications of radiotherapy]. Med Wieku Rozwoj; 2001 Jul-Sep;5(3 Suppl 1):25-35
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment regimen for children and adolescents with Hodgkin's disease designed to decrease late complications of radiotherapy].
  • Between 1997 to 1999 in 9 centres of the Polish Paediatlic Leukemia/Lymphoma Study Group, 167 children and adolescents (aged 2-19 years) with stage 1 to IV Hodgkin's disease (HD) were treated according to a regimen with a limited use of radiotherapy (RT).
  • All patients received B-DOPA and MVPP chemotherapy.
  • The number of cycles of chemotherapy was adjusted in respective risk groups.
  • In 13 children with stage IA and IIA disease with favourable prognostic factors chemotherapy alone was used.
  • In other patients the dose of RT applied to lymphatic regions was 15-46,4 Gy.
  • In case of a small tumour at presentation and good response to initial chemotherapy the RT dose was 15-16 Gy.
  • In other cases doses of 25-30 Gy were planned.
  • The use of higher doses, particularly exceeding 35 Gy, in eleven patients, was not justified.
  • Among all the 167 patients, three oftliem (1.2%) with advanced disease (Stage III-1V) did not achieve first remission.
  • All 13 children in whom chemotherapy alone was used remain in first remission.
  • In the group of children who received RT in the dose of 15-16 Gy relapse occurred in one child.
  • Our preliminary analysis indicates that limited use of RT in selected cases of HD in children and adolescents did not show worse results of treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Recurrence. Remission Induction. Risk. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12004149.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


25. Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, Dörken B, Hossfeld DK, Diehl V, Engert A, Participating Centers: Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol; 2002 Oct;13(10):1628-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
  • BACKGROUND: An important variable affecting outcome in relapsed and refractory Hodgkin's disease (HD) is the potential of conventional salvage chemotherapy to reduce tumor volume before high-dose chemotherapy (HDCT) and autologous stem cell transplantation.
  • Currently, the optimal salvage chemotherapy regimen for these patients is unclear.
  • Since dexamethasone/cisplatin/cytarabine (DHAP) given at 3-4 week intervals has been shown to be very effective in patients with relapsed aggressive non-Hodgkin's lymphoma, we evaluated this regimen given at a median of 16-day intervals in patients with relapsed and refractory HD.
  • PATIENTS AND METHODS: Patients with relapsed or refractory HD were treated with two cycles of DHAP [dexamethasone 40 mg intravenously (i.v.) day 1-4, cisplatin 100 mg/m(2) i.v. as 24-h continuous infusion day 1, and cytarabine 2 g/m(2) i.v.
  • Forty-two percent of the patients had late relapse, 29% early relapse, 12% multiple relapse and 16% primary progressive/refractory disease.
  • The RRs for patients with late, early, multiple and progressive HD were 91%, 93%, 92% and 65%, respectively.
  • Using the chi-square test for independence, remission status (relapsed HD versus progressive HD) and stage at relapse (stage I/II versus stage III/IV) were significant factors for response to DHAP.
  • Neither severe infections nor treatment-related deaths occurred.
  • CONCLUSIONS: A brief tumor-reducing program with two cycles of DHAP given in short intervals supported by G-CSF is effective and well-tolerated in patients with relapsed and refractory HD.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12377653.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Hentrich M, Maretta L, Chow KU, Bogner JR, Schürmann D, Neuhoff P, Jäger H, Reichelt D, Vogel M, Ruhnke M, Oette M, Weiss R, Rockstroh J, Arasteh K, Mitrou P: Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol; 2006 Jun;17(6):914-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study.
  • BACKGROUND: The purpose of the study was to evaluate the outcome of Hodgkin's disease (HD) in patients infected with the human immunodeficiency virus (HIV) with respect to the use of highly active antiretroviral therapy (HAART).
  • MATERIALS AND METHODS: This cohort study included patients with HIV-HD diagnosed from June 1984 to February 2004.
  • RESULTS: Of 66 patients with HIV-HD, 47 (71%) presented with stage III/IV disease and 38 patients (58%) with an AIDS-defining illness.
  • Fifty-nine of 66 patients (89.4%) underwent curative intended chemotherapy.
  • Three-year mortality was significantly higher in patients without complete remission (HR 4.40, CI 1.77-10.99), with stage III/IV HD (HR 4.64, CI 1.31-16.49) and with CD4 cells <200/microl (HR 2.69, CI 0.99-7.33).
  • CONCLUSIONS: Use of HAART significantly improved the overall survival in patients with HIV-HD.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565210.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


27. Gastaldi R, Martino P, Gentile G, Cafolla A, Cordone I, Giannini G, Torromeo C, Palmisano L, Picardi V, Andreotti M, Avvisati G, Mandelli F: High dose of idarubicin-based regimen for diffuse large cell AIDS-related non-Hodgkin's lymphoma patients: a pilot study. Haematologica; 2001 Oct;86(10):1051-9
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose of idarubicin-based regimen for diffuse large cell AIDS-related non-Hodgkin's lymphoma patients: a pilot study.
  • BACKGROUND AND OBJECTIVES: Intensive chemotherapy (CHT) in AIDS-related non-Hodgkin's lymphoma (AIDS-NHL patients) is a vexing problem.
  • Our purpose was to evaluate the feasibility of a high dose idarubicin (HD-IDA)-based regimen in diffuse large cell (DLC) AIDS-NHL patients.
  • DESIGN AND METHODS: Fourteen stage I-IV untreated DLC AIDS-NHL patients with a performance status <3 and no prior AIDS-related diseases received CIOD: cyclophosphamide, HD-IDA (25 mg/m2 in 8 patients, 20 mg/m2 in 6 patients) vincristine and dexamethasone plus granulocyte colony-stimulating factor (G-CSF) and prophylaxis against infections.
  • The outcomes measured were: rate of response, disease-free survival (DFS), overall survival (OS) and the impact of chemotherapy on immunologic and virological parameters.
  • The median time of response and survival was 33 (range 5-79) and 35.5 (range 6-84) months, respectively.
  • INTERPRETATION AND CONCLUSIONS: The proposed chemotherapeutic regimen for AIDS-related non-Hodgkin's lymphoma is feasible in an outpatient setting in selected patients with relatively well-preserved immune function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Idarubicin / administration & dosage. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / administration & dosage. Female. Humans. Male. Middle Aged. Pilot Projects. Treatment Outcome

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11602411.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; ZRP63D75JW / Idarubicin
  •  go-up   go-down


28. Bredenfeld H, Franklin J, Nogova L, Josting A, Fries S, Mailänder V, Oertel J, Diehl V, Engert A, German Hodgkin's Lymphoma Study Group: Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol; 2004 Jun 15;22(12):2424-9
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group.
  • PURPOSE: To investigate a new effective, nonleukemogenic polychemotherapy regimen, BAGCOPP (bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, gemcitabine) in a phase I/II dose-escalation study in patients with advanced-stage Hodgkin' s disease (HD).
  • PATIENTS AND METHODS: Patients in clinical stages IIB with risk factors III and IV were enrolled in this nonrandomized, multicenter trial aimed at defining the maximum-tolerated dose of gemcitabine within a modified escalated BEACOPP regimen.
  • A total of eight patients developed lung toxicity, mainly pneumonitis (six of eight), which led to the termination of the study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Etoposide / administration & dosage. Hodgkin Disease / diet therapy. Lung Diseases / chemically induced
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Feasibility Studies. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Pulmonary Disease.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15136597.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; B76N6SBZ8R / gemcitabine; VB0R961HZT / Prednisone
  •  go-up   go-down


29. Sun XF, Zhen ZJ, Liu DG, Xia Y, Xiang XJ, Chen XQ, Ling JY, Zheng L, Luo WB, Lin H, He YJ, Guan ZZ: [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents]. Ai Zheng; 2007 Dec;26(12):1339-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
  • BACKGROUND & OBJECTIVE: Burkitt's lymphoma is an aggressive non-Hodgkin's lymphoma (NHL) and often involves bone marrow and central nerve system.
  • The efficacy of CHOP regimen on Burkitt's lymphoma is poor.
  • The optimal chemotherapy regimen needs to be investigated.
  • This study was to evaluate the efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in children and adolescents, and observe the survival status.
  • 2006, 31 untreated Burkitt's lymphoma patients aged less than 20 were enrolled.
  • According to St Jude staging system, 1 (3.2%) was at stage I, 6 (19.4%) at stage II, 8 (25.8%) at stage III, 16 (51.6%) at stage IV; 24 (77.4%) were at stage III/IV.
  • According to clinical stage, lactate dehydrogenase (LDH) level and treatment response, these patients were divided into low, moderate and high risk groups.
  • They received modified B-NHL-BFM-90 protocol: cytotoxic drugs such as cyclophosphamide, vincristine, ifosfamide, etoposide, adriamycin, HD-methotrexate, vindesin, dexamethasone, cytarabinec/HD-cytarabine and intrathecal injection.
  • Of the 30 patients, 25 (83.3%) achieved complete remission (CR), 3 (10.0%) achieved partial remission (PR), 2 (6.7%) had progressive disease (PD)û 1 had tumor relapse.
  • Grade 3-4 myelosuppression occurred in most patients and were recovered by active support care and did not affect next course of chemotherapy.
  • At a median follow-up of 33 months (range, 3-98 months), the 3-year event-free survival (EFS) rate was 86.0% for all patients, with 100% for stage I/II patients and 82.1% for stage III/IV patients, 100% for low risk group, 92.0% for moderate risk group, and 70.0% for high risk group.
  • CONCLUSIONS: Modified B-NHL-BFM-90 protocol can improve the responses and survival of Burkitt's lymphoma in Chinese children and adolescents, with tolerable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Infant. L-Lactate Dehydrogenase / blood. Leukopenia / chemically induced. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Staging. Remission Induction. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076797.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


30. Kochbati L, Boussen H, Benna F, Belhaj Ali Z, Gammoudi A, Bouaouina N, Besbes M, Ghilen L, Rahal K, Maalej M: [Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz]. Cancer Radiother; 2003 Oct;7(5):302-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz].
  • [Transliterated title] Tumeurs secondaires après traitement pour maladie de Hodgkin en Tunisie. Etude rétrospective à propos de 26 cas observés à l'institut Salah-Azaïz.
  • PURPOSE: To collect second cancers in patients treated for Hodgkin disease (HD) during adolescence and young adulthood at Salah Azaïz Institute of Tunis.
  • METHODS AND PATIENTS: We consider as second cancer all tumours other than HD observed in patients after treatment for HD.
  • RESULTS: Twenty-five patients among 614 treated for HD between 1975 and 1991 developed 26 secondary tumours (4.2%).
  • Mean age at the diagnosis of HD was 32.5 years (12-56).
  • HD was stage II (eight cases), stage III (14) and stage IV in three.
  • The first treatment was combined chemotherapy and radiotherapy in 22 cases and only chemotherapy in three cases (stage IV).
  • Mean dose was 41.3 Gy (2 Gy/fraction in 21 and 3.3 in one).
  • Chemotherapy was MOPP (13), MOPP and vinblastine (four), MOPP-ABVD (five), ABVD (two) and vinblastine only in one.
  • There was five acute myeloid leukaemia, two digestive non-Hodgkin lymphomas, five nodal high-grade lymphomas, three breast cancers (one in man associated with thyroid cancer), five lung cancers (three non-small cell and two of small cell type), two gastric tumours and one rectal cancer, one synovialosarcoma of the knee and one malignant Schwannoma of the neck.
  • CONCLUSION: Second cancer risk after treatment for HD is not low.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Child. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Incidence. Male. Mechlorethamine / adverse effects. Middle Aged. Prednisone / adverse effects. Procarbazine / adverse effects. Retrospective Studies. Risk Factors. Tunisia / epidemiology. Vinblastine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14522350.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


34. Amini RM, Enblad G, Gustavsson A, Ekman T, Erlanson M, Haapaniemi E, Glimelius B: Treatment outcome in patients younger than 60 years with advanced stages (IIB-IV) of Hodgkin's disease: the Swedish National Health Care Programme experience. Eur J Haematol; 2000 Dec;65(6):379-89
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome in patients younger than 60 years with advanced stages (IIB-IV) of Hodgkin's disease: the Swedish National Health Care Programme experience.
  • BACKGROUND: Despite improved treatment results achieved in Hodgkin's disease (HD), only about 70% of patients with advanced stages are cured.
  • The primary aim of this study was to evaluate the outcome of advanced stages (IIB-IVB) of HD in younger patients in an unselected population-based group of patients.
  • The patients were recommended individualized treatment with respect to number of chemotherapy (CT) courses and post-CT radiotherapy (RT) based on pretreatment characteristics and tumour response.
  • PATIENTS AND METHODS: Between 1985-92, 307 patients between 17-59 yr of age (median 36) were diagnosed with HD in stages IIB-IVB in 5/6 health care regions in Sweden.
  • Median follow-up time was 7.8 yr (1.3-13).
  • The overall and disease-free 10-yr survivals in the whole cohort were 76% and 67%, respectively.
  • In univariate analyses survival was affected by age, stage IVB, bone-marrow involvement, B-symptoms, S-LDH, S-Alb and reaching CR or not after 2, 4 and 6 cycles of CT.
  • CONCLUSIONS: The lack of difference in survival between the groups of patients who received 6 versus 8 cycles of CT indicates a successful selection of patients for the shorter treatment.
  • [MeSH-major] Hodgkin Disease / pathology. Hodgkin Disease / therapy
  • [MeSH-minor] Actuarial Analysis. Adolescent. Adult. Antineoplastic Agents / therapeutic use. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. National Health Programs. Neoplasm Staging. Radiotherapy, Adjuvant. Recurrence. Retrospective Studies. Risk Factors. Survival Rate. Sweden / epidemiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11168495.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


35. Tsimberidou AM, Sarris AH, Medeiros LJ, Mesina O, Rodriguez MA, Hagemeister FB, Romaguera J, Pro B, McLaughlin P, Dang N, Cabanillas F: Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymphoma; 2001 May;41(5-6):535-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome.
  • We report the frequency, presenting characteristics, progression-free survival, event-free survival, overall survival and AIDS-free survival of patients with previously untreated Hodgkin's disease (HD) in the setting of infection by human immunodeficiency virus (HIV).
  • Anderson Cancer Center between July 1985 and August 1999 with HD and HIV infection.
  • All available records were reviewed to determine presentation, clinical characteristics, treatment outcome, progression-free survival and overall survival.
  • We identified 887 patients with HD and 3,500 with Non-Hodgkin's Lymphoma (NHL).
  • The ratio of NHL to HD in HIV-negative versus HIV-positive patients was 3.9 versus 6.9, respectively.
  • There were 14 HIV-positive patients with HD and 97 with NHL.
  • The median age of the HIV-positive HD patients was 33 years, and 13 were male.
  • Three patients had Acquired Immune Deficiency syndrome (AIDS) at the time of HD diagnosis, and seven had B-symptoms.
  • Ann Arbor stage was I in one, II in three, III in four and IV in six patients.
  • Mixed cellularity histology was seen in eight, bone marrow involvement in five and extranodal disease in seven patients.
  • All patients received some antiretroviral therapy, but it was variable over the years.
  • Six patients died of complications arising from HIV infection, including one patient who had preexisting AIDS at HD presentation.
  • Two patients died of HD, without developing other conditions diagnostic of AIDS.
  • We conclude that in our referral patient population HIV infection is associated with preferential development of NHL rather than HD, which appears curable with standard treatment regimens.
  • Since HIV-related deaths exceed those caused by HD, future investigation should focus on integration of chemotherapy and highly active antiretroviral therapy.
  • [MeSH-major] Hodgkin Disease / virology. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / mortality
  • [MeSH-minor] Actuarial Analysis. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antiviral Agents / administration & dosage. Female. Humans. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / virology. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11378571.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


36. Fitoussi, Eghbali H, Tchen N, Berjon JP, Soubeyran P, Hoerni B: Semen analysis and cryoconservation before treatment in Hodgkin's disease. Ann Oncol; 2000 Jun;11(6):679-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Semen analysis and cryoconservation before treatment in Hodgkin's disease.
  • BACKGROUND: The prophylaxis of the late effects of chemotherapy and radiotherapy has become one of the major concerns in the management of Hodgkin's disease (HD).
  • PATIENTS AND METHODS: To evaluate the semen quality of patients with HD and the outcome of insemination, we reviewed spermograms of patients who underwent SP before any treatment.
  • 2) HD of any stage;.
  • 3) informed about male sterility after HD treatment;.
  • All patients underwent an initial chemotherapy.
  • Pretherapeutic staging of HD revealed 38 stage I (40%), 38 II (38%), 14 III (15%) and 4 IV (4%).
  • The analysis of semen quality and spermatozoid amount according to various parameters failed to find a correlation with stage, B symptoms, age, or biologic data (LDH, WBC, platelets, ESR).
  • CONCLUSIONS: The low rate of success with cryopreserved semen in these cases suggests the need for a more careful design of non-toxic chemotherapy regimens in combined modality treatment.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10942055.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Gebert C, Hardes J, Ahrens H, Buerger H, Winkelmann W, Gosheger G: Primary multifocal osseous Hodgkin disease: a case report and review of the literature. J Cancer Res Clin Oncol; 2005 Mar;131(3):163-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary multifocal osseous Hodgkin disease: a case report and review of the literature.
  • PURPOSE: Hodgkin disease (HD) typically involves the lymphatic system at one or more sites.
  • Rarely, Hodgkin disease presents as an osseous lesion without involvement of lymph nodes.
  • Therefore, the histologic diagnosis of osseous HD can be problematic.
  • We present a rare case of multifocal osseous HD and a review the literature with special emphasis on treatment and prognosis.
  • METHODS: Osteomyelitis and lymphoma are the main differential diagnoses and can only be excluded histologically by the presence of Sternberg Reed cells or by immunohistochemical examinations.
  • This case reports a 21-year old man with a Hodgkin lymphoma located at the proximal femur and the proximal tibia.
  • Regarding the Ann Arbor classification, the presented case should be a stage IV disease.
  • The patient is without evidence of disease 4 years after curettage, local radiation therapy, and systemic chemotherapy despite the poor prognosis considering the Ann Arbor classification.
  • CONCLUSION: Reviewing the few reported cases, osseous HD must be distinguished from systemic HD with diffuse bone marrow involvement and from osseous metastases in advanced stage of disease because it seems to have a better prognosis.
  • [MeSH-major] Bone Neoplasms / diagnosis. Hodgkin Disease / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Femur / diagnostic imaging. Femur / pathology. Humans. Immunohistochemistry. Lymphoma / diagnosis. Male. Osteomyelitis / diagnosis. Radiography. Tibia / diagnostic imaging. Tibia / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 1992 Oct;(283):276-80 [1395259.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):536-44 [9469338.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2386-95 [12802024.001]
  • [Cites] Ann Hematol. 1992 Aug;65(2):61-5 [1324741.001]
  • [Cites] Cancer. 1982 Jan 15;49(2):338-42 [7053832.001]
  • [Cites] CMAJ. 1989 May 1;140(9):1059-60 [2706592.001]
  • [Cites] Br J Surg. 1969 Apr;56(4):277-81 [4952475.001]
  • [Cites] Semin Oncol. 1990 Dec;17(6):683-95 [2251515.001]
  • [Cites] Skeletal Radiol. 1995 Jan;24(1):61-3 [7709257.001]
  • [Cites] Radiology. 1961 Jul;77:53-60 [13702399.001]
  • [Cites] Semin Oncol. 1980 Jun;7(2):174-83 [7444471.001]
  • [Cites] Cancer Treat Rev. 1986 Jun;13(2):77-111 [3527412.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1079-85 [15205202.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):476-83 [10507773.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):79-88 [8630944.001]
  • [Cites] Cancer. 1998 Sep 1;83(5):1041-7 [9731909.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1166-78 [10091803.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2234-6 [6488141.001]
  • [Cites] Radiol Clin North Am. 1990 Jul;28(4):841-64 [2190273.001]
  • [Cites] J Clin Oncol. 1985 Feb;3(2):215-21 [2981984.001]
  • [Cites] Cancer Treat Rep. 1982 Apr;66(4):1035-44 [6951632.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1509-17 [7417953.001]
  • [Cites] Rontgenpraxis. 2003;55(3):114-24 [15119314.001]
  • [Cites] Am J Hematol. 1989 Mar;30(3):115-20 [2644822.001]
  • [Cites] Br J Radiol. 1967 Dec;40(480):939-48 [4952885.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1052-5 [4016696.001]
  • [Cites] Ann Intern Med. 1985 Jan;102(1):37-41 [3966743.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:98-101 [12078913.001]
  • [Cites] Cancer. 1984 Jan 15;53(2):232-6 [6360333.001]
  • [Cites] N Engl J Med. 1964 Mar 5;270:508-14 CONTD [14089119.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1965 Mar;93:568-72 [14259982.001]
  • [Cites] Oncology. 2001;60(2):101-9 [11244323.001]
  • [Cites] Skeletal Radiol. 1979;4(4):233-5 [531588.001]
  • [Cites] Med Pediatr Oncol. 1995 Mar;24(3):204-7 [7530802.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1972 Mar;114(3):559-63 [4110941.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1786-93 [5121683.001]
  • [Cites] Australas Radiol. 1993 Feb;37(1):63-6 [8323514.001]
  • (PMID = 15605165.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


38. Mariani A, Webb MJ, Keeney GL, Calori G, Podratz KC: Hematogenous dissemination in corpus cancer. Gynecol Oncol; 2001 Feb;80(2):233-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of this study was to assess the predictors of hematogenous dissemination (HD) in corpus cancer.
  • METHODS: In 612 corpus cancer patients managed surgically, we defined HD as tumor spread to the lung, liver, or other sites via hematogenous routes.
  • Stage IV disease, positive adnexae, deep myometrial invasion, primary tumor diameter, tumor involving the whole uterine cavity, positive peritoneal cytology, adjuvant radiotherapy, adjuvant chemotherapy, grade 3 histology, histologic subtype, and lymph-vascular invasion significantly (P < or = 0.01) correlated with HD.
  • However, deep myometrial invasion was the only independent predictor of HD.
  • Only 5% of patients with < or = 50% myometrial invasion had HD compared with 23% with > 50% myometrial invasion.
  • Considering separately recurrence in the lung and in the liver and recurrence in other sites, the only independent predictors of lung recurrence were stage IV disease and myometrial invasion, whereas independent predictors of HD to the liver/other sites were age and histologic grade.
  • Considering only the 60 patients with a known site of HD, 67% with lung recurrence were > 65 years old compared with 17% with HD to the liver/other sites.
  • Furthermore, grade 1-2 disease was observed in 65% of patients with lung recurrence compared with 27% with HD to the liver/other sites.
  • CONCLUSIONS: The presence of deep myometrial invasion was the strongest predictor of HD in corpus cancer, and, together with stage IV disease, it independently predicted lung recurrence.
  • Recurrence in the lung was more frequent in older patients with well or moderately differentiated tumors, whereas HD to the liver/other sites was more frequent in patients < or = 65 years of age harboring grade 3 tumors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Risk Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11161865.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30CA15083
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


39. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, Rudolph C, Diehl V, Engert A: New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol; 2002 Jan 01;20(1):221-30
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group.
  • PURPOSE: To evaluate salvage treatment outcome of patients with relapsed Hodgkin's disease (HD) and to distinguish different risk groups using identified prognostic factors.
  • PATIENTS AND METHODS: From 4,754 patients registered in the German Hodgkin's Lymphoma Study Group (GHSG) database between 1988 and 1999, 422 patients with early (n = 170) or late (n = 252) relapsed HD were identified.
  • One hundred seven patients (25%) relapsed after radiotherapy (RT) for early stages, 133 patients (32%) after combined-modality therapy for intermediate stages, and 182 patients (43%) after chemotherapy (CT) and RT to initial bulky disease or residual lymphoma for advanced stages.
  • At relapse, characteristics of these 422 patients (median age, 38 years; range, 17 to 77) were stage III/IV, 45%; B symptoms, 24%; elevated erythrocyte sedimentation rate, 29%; anemia, 13%; and Karnofsky performance score, less than 90 in 13%.
  • At first relapse, salvage treatment was RT in 13%, CT in 54%, and high-dose chemotherapy (HDCT) with autologous stem-cell transplantation (ASCT) in 33%.
  • RESULTS: Median follow-up time after relapse was 45 months.
  • In multivariate analysis, independent risk factors were time to relapse, clinical stage at relapse, and anemia at relapse.
  • CONCLUSION: In the GHSG database, time to relapse and clinical stage and anemia at relapse are relevant factors and can be used to form a prognostic score for HD patients at relapse.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Salvage Therapy
  • [MeSH-minor] Actuarial Analysis. Adolescent. Adult. Aged. Analysis of Variance. Combined Modality Therapy. Female. Follow-Up Studies. Germany / epidemiology. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Recurrence. Risk Factors. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11773173.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


40. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res; 2005 Oct 1;65(19):8961-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have determined the methylation frequencies of 24 CpG islands of genes associated with DNA damage responses or with ovarian cancer in 106 stage III/IV epithelial ovarian tumors.
  • We have analyzed this data for whether there is evidence of a CpG island methylator phenotype or associations of CpG island methylation with response to chemotherapy in advanced ovarian cancer.
  • Methylation of at least one of the group of genes involved in DNA repair/drug detoxification (BRCA1, GSTP1, and MGMT) was associated with improved response to chemotherapy (P = 0.013).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CpG Islands. DNA (Cytosine-5-)-Methyltransferase / genetics. DNA Methylation. Female. Genotype. Humans. Middle Aged. Neoplasm Staging. Polymorphism, Genetic


41. Lee JK, Tsai SC, Ho YJ, Changlai SP, Kao CH: Technetium-99m tetrofosmin scintigraphy for detecting malignant lymphoma. Anticancer Res; 2001 Mar-Apr;21(2B):1509-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Technetium-99m tetrofosmin scintigraphy for detecting malignant lymphoma.
  • In the study, before any chemotherapy, 50 patients with malignant lymphoma underwent Tc-TF scintigraphy, which was performed 10 minutes after intravenous injection of 20 mCt Tc-TF.
  • Tc-TF scintigraphy detected malignant lymphoma in 44 (88%) patients.
  • However, there were no significant differences in the incidences of positive and negative Tc-TF scintigraphic results between female versus male patients, HD versus NHL patients, stage I-II versus stage III-IV patients, age > 40 years versus < or = 40 years patients and patients with B symptoms false-negative results occurred in 4 (8%) infradiaphragmatic malignant lymphoma.
  • We conclude patients with that Tc-TF scintigraphy appears suitable for detecting malignant lymphoma, especially supradiaphragmatic lesions.
  • [MeSH-major] Lymphoma / diagnosis. Organophosphorus Compounds. Organotechnetium Compounds. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11396241.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


42. Vigouroux S, Milpied N, Andrieu JM, Colonna P, Ifrah N, Colombat P, Desablens B, Abgrall JF, Casassus P, Guilhot F, Briere J, Le Mevel A, Moreau P, Mechinaud F, Mahe B, Morineau N, Vigier M, Rapp MJ, Harousseau JL: Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy. Bone Marrow Transplant; 2002 May;29(10):833-42
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy.
  • This retrospective study compares high-dose therapy (HDT) with autologous stem cell transplantation and combined-modality treatment (CT) as a first-line therapy for Hodgkin's disease (HD) for patients with both a clinical stage (CS) IV and/or a mediastinal mass > or =0.45 of the thoracic diameter (MM > or =0.45) at diagnosis, and an incomplete response after the first-line chemotherapy.
  • Both groups were comparable except for pulmonary disease in excess in the grafted group (P = 0.01).
  • Among GP, 95% were in complete response at the end of first-line treatment and 77% among CTP.
  • Similar results were obtained for the groups with a response > or =50% after initial chemotherapy: 91% vs 65% for FFP, P = 0.01; 87% vs 61% for EFS, P = 0.02; and 92% vs 77% for OS, P = 0.2; and for the groups with a response <50%: 80% vs 22% for FFP, P = 0.0003; 72% vs 13% for EFS, P = 0.0001; and 76% vs 46% for OS, P = 0.04.
  • This study shows a better control of the disease with HDT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Clinical Protocols. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors. Transplantation, Autologous. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12058233.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. Schleinitz MD, DePalo D, Blume J, Stein M: Can differences in breast cancer utilities explain disparities in breast cancer care? J Gen Intern Med; 2006 Dec;21(12):1253-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Black, older, and less affluent women are less likely to receive adjuvant breast cancer therapy than their counterparts.
  • OBJECTIVE: To ascertain utilities from women of diverse backgrounds for the different stages of, and treatments for, breast cancer and to determine whether a treatment decision modeled from utilities is associated with socio-demographic characteristics.
  • PARTICIPANTS: A stratified sample (by age and race) of 156 English-speaking women over 25 years old not currently undergoing breast cancer treatment.
  • DESIGN AND MEASUREMENTS: We assessed utilities using standard gamble for 5 breast cancer stages, and time-tradeoff for 3 therapeutic modalities.
  • We incorporated each subject's utilities into a Markov model to determine whether her quality-adjusted life expectancy would be maximized with chemotherapy for a hypothetical, current diagnosis of stage II breast cancer.
  • RESULTS: Median utilities for the 8 health states were: stage I disease, 0.91 (interquartile range 0.50 to 1.00); stage II, 0.75 (0.26 to 0.99); stage III, 0.51 (0.25 to 0.94); stage IV (estrogen receptor positive), 0.36 (0 to 0.75); stage IV (estrogen receptor negative), 0.40 (0 to 0.79); chemotherapy 0.50 (0 to 0.92); hormonal therapy 0.58 (0 to 1); and radiation therapy 0.83 (0.10 to 1).
  • Utilities for early stage disease and treatment modalities, but not metastatic disease, varied with socio-demographic characteristics.
  • One hundred and twenty-two of 156 subjects had utilities that maximized quality-adjusted life expectancy given stage II breast cancer with chemotherapy.
  • Age over 50, black race, and low household income were associated with at least 5-fold lower odds of maximizing quality-adjusted life expectancy with chemotherapy, whereas women who were married or had a significant other were 4-fold more likely to maximize quality-adjusted life expectancy with chemotherapy.
  • CONCLUSIONS: Differences in utility for breast cancer health states may partially explain the lower rate of adjuvant therapy for black, older, and less affluent women.
  • Further work must clarify whether these differences result from health preference alone or reflect women's perceptions of sources of disparity, such as access to care, poor communication with providers, limitations in health knowledge or in obtaining social and workplace support during therapy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] WMJ. 1999 Dec;98(8):37-9 [10639893.001]
  • [Cites] J Gen Intern Med. 2005 Jan;20(1):38-44 [15693926.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3302-17 [10986064.001]
  • [Cites] Oncol Nurs Forum. 2000 Nov-Dec;27(10):1555-64 [11103374.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1455-61 [11230491.001]
  • [Cites] Br J Cancer. 2001 Jun 15;84(12):1577-85 [11401308.001]
  • [Cites] Natl Vital Stat Rep. 2001 Sep 21;49(8):1-113 [11591077.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):334-57 [11880473.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):471-3 [11929941.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2844-54 [12115371.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1759-66 [12365025.001]
  • [Cites] South Med J. 2002 Oct;95(10):1145-8 [12425498.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):134-47 [12491515.001]
  • [Cites] Cancer Metastasis Rev. 2003 Mar;22(1):55-65 [12716037.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):803-19 [12875597.001]
  • [Cites] Breast Cancer Res Treat. 2003 Sep;81(1):21-31 [14531494.001]
  • [Cites] BMC Med Inform Decis Mak. 2001;1:2 [11545684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):34-42 [14697418.001]
  • [Cites] J Gen Intern Med. 2004 Feb;19(2):184-94 [15009798.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Med Decis Making. 2005 May-Jun;25(3):301-7 [15951457.001]
  • [Cites] Arch Fam Med. 1999 Nov-Dec;8(6):521-8 [10575392.001]
  • [Cites] Med Decis Making. 2000 Jan-Mar;20(1):72-8 [10638539.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):311-7 [12491494.001]
  • [Cites] Arch Intern Med. 2003 Jan 13;163(1):49-56 [12523916.001]
  • [Cites] Ann Intern Med. 2003 Jan 21;138(2):90-7 [12529090.001]
  • [Cites] J Eval Clin Pract. 2003 Feb;9(1):69-82 [12558704.001]
  • [Cites] Med Decis Making. 2003 Mar-Apr;23(2):167-76 [12693879.001]
  • [Cites] Prev Med. 2004 Jul;39(1):1-10 [15207980.001]
  • [Cites] CA Cancer J Clin. 2003 Nov-Dec;53(6):342-55 [15224974.001]
  • [Cites] Clin Prostate Cancer. 2004 Jun;3(1):31-7 [15279688.001]
  • [Cites] Health Serv Res. 1972 Summer;7(2):118-33 [5044699.001]
  • [Cites] Med Decis Making. 1982 Winter;2(4):449-62 [7182703.001]
  • [Cites] J Health Econ. 1986 Mar;5(1):1-30 [10311607.001]
  • [Cites] Med Care. 1989 Mar;27(3 Suppl):S190-204 [2522159.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86 [2593165.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):326-31 [8321261.001]
  • [Cites] Med Decis Making. 1993 Jul-Sep;13(3):212-7 [8412549.001]
  • [Cites] Cancer. 1996 Oct 1;78(7):1395-402 [8839544.001]
  • [Cites] Breast Cancer Res Treat. 1996;39(3):261-73 [8877006.001]
  • [Cites] Breast Cancer Res Treat. 1996;40(1):65-74 [8888153.001]
  • [Cites] Am J Prev Med. 1996 Sep-Oct;12(5):327-37 [8909641.001]
  • [Cites] Med Decis Making. 1997 Jan-Mar;17(1):21-32 [8994148.001]
  • [Cites] Med Decis Making. 1997 Apr-Jun;17(2):136-41 [9107608.001]
  • [Cites] Oncol Nurs Forum. 1998 Apr;25(3):555-62 [9568610.001]
  • [Cites] Oncol Nurs Forum. 1998 Jun;25(5):887-95 [9644705.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1409-15 [10451447.001]
  • [Cites] J Clin Epidemiol. 1999 Nov;52(11):1047-53 [10526998.001]
  • [Cites] Med Care. 2005 Feb;43(2):141-8 [15655427.001]
  • [Cites] Med Care. 2000 Sep;38(9 Suppl):II160-4 [10982102.001]
  • (PMID = 16961753.001).
  • [ISSN] 1525-1497
  • [Journal-full-title] Journal of general internal medicine
  • [ISO-abbreviation] J Gen Intern Med
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD043447; United States / NICHD NIH HHS / HD / HD43447
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones; 0 / Receptors, Estrogen
  • [Other-IDs] NLM/ PMC1924747
  •  go-up   go-down


44. Renedo RJ, Sousa MM, Pérez SF, Zabalbeascoa JR, Carro LP: Avascular necrosis of the femoral head in patients with Hodgkin's disease. Hip Int; 2010 Oct-Dec;20(4):473-81
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Avascular necrosis of the femoral head in patients with Hodgkin's disease.
  • Avascular necrosis of the femoral head (ANFH) is a rare complication that may occur in patients diagnosed with Hodgkin's Disease (HD), as a result of treatment.
  • A review was made of 315 cases of HD treated with systemic chemotherapy associated with high doses of steroids and radiation therapy and 18 patients (5.71%) were found to have developed ANFH during treatment.
  • The mean follow-up time for chemotherapy was 40 months (range 20-110 months) with an average dose of prednisone of 8.45 g (range 3.20 - 18.50).
  • In 8 cases (44.44%) forage associated with IES was performed as the initial treatment option and 6 of these cases were found to be in Ficat stage II (75%), 1 was found to be in stage III (12.55%) and another in stage IV (12.5%).
  • In 2 cases, the central decompression technique was used (Simple Forage); both were in Ficat stage II.
  • In the other 8 cases, a total hip arthroplasty (THA) was chosen as the initial treatment option, with 3 of these patients in Ficat stage III and 5 in Ficat stage IV.
  • The clinical outcomes (time to postoperative pain, time to radiological failure, and time to arthroplasty from the forage) following surgical management using the forage-biopsy technique with and without internal electrostimulation (IES) were recorded.
  • We observed that treatment with Forage + IES was better than simple Forage in stages below III in patients with Hodgkin's Disease.
  • We considered that in Ficat stage III and IV arthroplasty (THA) was the better option.
  • [MeSH-major] Femur Head Necrosis / pathology. Hodgkin Disease / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Arthroplasty, Replacement, Hip. Decompression, Surgical. Electric Stimulation Therapy. Female. Glucocorticoids / adverse effects. Humans. Male. Middle Aged. Prednisone / adverse effects. Radiotherapy, Adjuvant. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21157752.001).
  • [ISSN] 1724-6067
  • [Journal-full-title] Hip international : the journal of clinical and experimental research on hip pathology and therapy
  • [ISO-abbreviation] Hip Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; VB0R961HZT / Prednisone
  •  go-up   go-down


45. Irish A, Dogra G, Mori T, Beller E, Heritier S, Hawley C, Kerr P, Robertson A, Rosman J, Paul-Brent PA, Starfield M, Polkinghorne K, Cass A: Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrol; 2009;10:1
Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.
  • BACKGROUND: Haemodialysis (HD) is critically dependent on the availability of adequate access to the systemic circulation, ideally via a native arteriovenous fistula (AVF).
  • METHODS/DESIGN: The study population is adult patients with stage IV or V chronic kidney disease (CKD) currently on HD or where HD is planned to start within 6 months in whom a planned upper or lower arm AVF is to be the primary HD access.
  • Using a factorial-design trial, patients will be randomised to aspirin or matching placebo, and also to omega-3 fatty acids or matching placebo, resulting in four treatment groups (aspirin placebo/omega-3 fatty acid placebo, aspirin/omega-3 fatty acid placebo, aspirin placebo/omega-3 fatty acid, aspirin/omega-3 fatty acid).
  • The medication will be commenced pre-operatively and continued for 3 months post surgery.
  • Secondary outcome measures will include functional patency at six and twelve months, primary patency time, secondary (assisted) patency time, and adverse events, particularly bleeding.
  • [MeSH-major] Arteriovenous Shunt, Surgical / adverse effects. Aspirin / therapeutic use. Docosahexaenoic Acids / therapeutic use. Eicosapentaenoic Acid / therapeutic use. Platelet Aggregation Inhibitors / therapeutic use. Thrombosis / prevention & control. Vascular Patency / drug effects
  • [MeSH-minor] Adult. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Clinical Protocols. Double-Blind Method. Drug Combinations. Humans. Kidney Failure, Chronic / complications. Kidney Failure, Chronic / therapy. Multicenter Studies as Topic / methods

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Dial. 2000 Jan-Feb;13(1):40-6 [10740671.001]
  • [Cites] JAMA. 2008 May 14;299(18):2164-71 [18477783.001]
  • [Cites] Circulation. 2000 Sep 12;102(11):1264-9 [10982541.001]
  • [Cites] J Ren Nutr. 2000 Oct;10(4):191-5 [11070146.001]
  • [Cites] Nephrol Dial Transplant. 2000 Nov;15(11):1865-8 [11071979.001]
  • [Cites] Br J Surg. 2001 Feb;88(2):261-6 [11167878.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2001 Jun;64(6):291-7 [11427037.001]
  • [Cites] J Am Soc Nephrol. 2002 Jan;13(1):184-90 [11752036.001]
  • [Cites] J Vasc Surg. 2002 Mar;35(3):603-10 [11877717.001]
  • [Cites] Thromb Res. 2002 Feb 15;105(4):311-6 [12031825.001]
  • [Cites] Eur J Clin Invest. 2002 Jun;32(6):429-36 [12059988.001]
  • [Cites] Kidney Int. 2002 Aug;62(2):620-6 [12110026.001]
  • [Cites] Kidney Int. 2002 Oct;62(4):1109-24 [12234281.001]
  • [Cites] Am J Clin Nutr. 2002 Nov;76(5):1007-15 [12399272.001]
  • [Cites] Atherosclerosis. 2003 Jan;166(1):85-93 [12482554.001]
  • [Cites] J Am Soc Nephrol. 2004 Feb;15(2):477-86 [14747396.001]
  • [Cites] BMC Clin Pharmacol. 2001;1:1 [11228592.001]
  • [Cites] Redox Rep. 2004;9(4):193-7 [15479562.001]
  • [Cites] Curr Atheroscler Rep. 2004 Nov;6(6):461-7 [15485592.001]
  • [Cites] Klin Wochenschr. 1974 Apr 1;52(7):348-9 [4600820.001]
  • [Cites] Lancet. 1986 Feb 22;1(8478):414-6 [2868341.001]
  • [Cites] J Clin Invest. 1987 Jun;79(6):1788-97 [3108321.001]
  • [Cites] Lancet. 1988 Jan 16;1(8577):119 [2891958.001]
  • [Cites] Nephron. 1990;55(4):445-7 [2202923.001]
  • [Cites] Nephrol Dial Transplant. 1994;9(8):1115-20 [7800210.001]
  • [Cites] Food Chem Toxicol. 1995 Jul;33(7):553-8 [7628790.001]
  • [Cites] Scand J Urol Nephrol. 1998 Jul;32(4):276-83 [9764456.001]
  • [Cites] J Am Soc Nephrol. 1999 Oct;10(10):2177-84 [10505695.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2004 Dec;28(6):583-9 [15531191.001]
  • [Cites] J Am Soc Nephrol. 2005 Jan;16(1):201-9 [15563567.001]
  • [Cites] Am J Kidney Dis. 2005 Mar;45(3):473-84 [15754269.001]
  • [Cites] Kidney Int. 2005 Jul;68(1):311-8 [15954922.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Mar;1(2):182-92 [17699207.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Mar;1(2):246-55 [17699213.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Mar;1(2):332-9 [17699225.001]
  • [Cites] Am J Clin Nutr. 2000 May;71(5):1085-94 [10799369.001]
  • (PMID = 19159453.001).
  • [ISSN] 1471-2369
  • [Journal-full-title] BMC nephrology
  • [ISO-abbreviation] BMC Nephrol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Drug Combinations; 0 / Omacor; 0 / Platelet Aggregation Inhibitors; 25167-62-8 / Docosahexaenoic Acids; AAN7QOV9EA / Eicosapentaenoic Acid; R16CO5Y76E / Aspirin
  • [Other-IDs] NLM/ PMC2637871
  •  go-up   go-down


46. St Peter WL, Obrador GT, Roberts TL, Collins AJ: Trends in intravenous iron use among dialysis patients in the United States (1994-2002). Am J Kidney Dis; 2005 Oct;46(4):650-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Two new intravenous (IV) iron products, ferric gluconate and iron sucrose, recently were approved for use in the United States.
  • We report trends in IV iron use in both incident (1994 to 2001) and prevalent (1994 to 2002) Medicare US dialysis patients.
  • Recombinant human erythropoietin doses, IV iron use, and hemoglobin data were obtained from Medicare outpatient files.
  • The most recent cohorts included 241,770 prevalent hemodialysis (HD) patients in 2002 and 11,744 incident HD patients in 2001.
  • RESULTS: For incident HD patients in the first 9 months of dialysis therapy, the percentage of patients administered IV iron increased sharply between 1994 and 1997 and then increased gradually between 1997 and 2001.
  • In 2002, a total of 84.4% of HD and 19.3% of peritoneal dialysis (PD) patients were administered IV iron.
  • The absolute monthly percentage of HD patients administered IV iron dextran decreased from 49.6% in January 2000 to 3.6% in December 2002.
  • CONCLUSION: In US patients with end-stage renal disease, IV iron use has increased, although slowly, from 1997 to 2002.
  • Ferric gluconate and iron sucrose have become the predominant form of therapy.
  • IV iron therapy was used in a much smaller percentage of PD compared with HD patients, and racial and geographic variability was observed.
  • [MeSH-major] Anemia, Hypochromic / drug therapy. Ferric Compounds / administration & dosage. Kidney Failure, Chronic / complications. Renal Dialysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Drug Utilization / trends. Erythropoietin / therapeutic use. Female. Glucaric Acid. Humans. Incidence. Infant. Infusions, Intravenous. Male. Medicare / statistics & numerical data. Middle Aged. Outpatients. Peritoneal Dialysis / statistics & numerical data. Prevalence. Recombinant Proteins. Retrospective Studies. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16183420.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / N01-DK-9-2343
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ferric Compounds; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; 88088-23-7 / ferric gluconate; FZ7NYF5N8L / ferric oxide, saccharated; QLZ991V4A2 / Glucaric Acid
  •  go-up   go-down


47. Smolewski P, Robak T, Krykowski E, Blasiñska-Morawiec M, Niewiadomska H, Pluzanska A, Chmielowska E, Zambrano O: Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res; 2000 Mar;6(3):1150-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution.
  • On the basis of a retrospective study of 327 patients with Hodgkin's disease (HD), the prognostic significance of several factors, accepted previously and recently proposed, has been analyzed with regard to response to treatment and the survival time.
  • The only independent, pretreatment factors negatively influenced by either time of survival or response to treatment were the following: age at diagnosis of more than 45 years, advanced (IIIB/IV) clinical stage, poor clinical status according to Karnofsky's scale (score less than 70), presence of systemic symptoms, mixed cellularity/lymphocyte depletion histological type, multisite peripheral nodal localization of the disease, abdominal lymphadenopathy, and large primary tumor mass (bulky disease).
  • Short time to achieve complete remission (during the first four courses of chemotherapy) has proven to be significantly positive predictive factor.
  • Cumulative dose of cytostatics lower than programmed was a significantly negative prognostic factor that correlated with a shorter time of survival.
  • High activity of serum lactate dehydrogenase correlated moderately with poor response to the first-line treatment but did not influence the survival time.
  • Other clinical, morphological, and biochemical parameters influenced neither the prognosis nor the response to treatment.
  • Additionally, immunohistochemical examinations for proliferating cell nuclear antigen and the protein products of the p53 and bcl-2 genes were performed on the lymph nodes obtained from the patients with HD.
  • High expression of proliferating cell nuclear antigen, p53, and BCL-2 correlated with poor response to the treatment and/or short time of survival.
  • Statistical analysis has led us to the conclusion that the pretreatment expression of these oncoproteins can be taken into consideration as a new prognostic factor in HD.
  • [MeSH-major] Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Proliferating Cell Nuclear Antigen / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Retrospective Studies. Survival Analysis. Treatment Outcome. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Cancer Res 2000 May;6(5):2120
  • (PMID = 10741746.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


48. Gocheva L, Koleva I: Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience. Klin Onkol; 2010;23(1):34-42
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience.
  • BACKGROUND: To establish the efficacy of the combined modality treatment (CMT) including curative extended field radiotherapy (EFRT) and chemotherapy (CHT) by examining the long-term outcome in Hodgkin's disease (HD) patients at the Sofia University Hospital "Queen Giovanna-ISUL", with particular focus on second primary malignancy (SPM), and to establish independent factors correlated with treatment outcome.
  • METHODS AND MATERIALS: Between 1982 and 2007, 170 patients with HD with median age of 12 years (range 3-40), (68 females, 102 males), were included in this retrospective study.
  • The clinical stage (CS) distribution was CS I in 1 patient (0.6%), CS II in 86 (50.5%), CS III in 77 (45.3%) and CS IV in 6 (3.5%) patients.
  • The overall treatment consisted of both EFRT and CHT.
  • The daily dose was 1.5-2 Gy, the total dose for EFRT was 20-40 Gy.
  • RESULTS: Follow-up extended from a minimum of 0,3 years to maximum 25,7 years, with a median observation time 12 years.The 5-, 10-, 15-, and 25-year overall survival (OS) in the whole group was 93% : 86% : 82% : 82%, respectively.
  • The following factors were analyzed for their prognostic influence: age, gender, stage, histologic subtype at first diagnosis, sites of involvement, number of involved lymph node areas, B symptoms, hepatosplenomegaly, anemia, elevated serum LDH, daily dose, total dose, boost and technique used in EFRT.
  • In univariate analysis, independent risk factors were gender (p < 0.001), stage (IIB: IIIA) (p = 0.03), mediastinal involvement (p = 0.03), daily dose (p = 0.01) and total dose (p = 0.02).
  • In multivariate analysis, independent risk factors age < or = 15 years (p < 0.001), male gender (p = 0.005), daily dose < or = 1.5 Gy (p = 0.009), and total dose 26-30 Gy (p = 0.048) were found to positively affect OS.
  • We investigated a prognostic model, identifying groups of HD patients with particularly responsive disease, combining prognostic factors as age < or = 15 years (p = 0.001), male gender (p = 0.011), and total dose 26-30 Gy (p = 0.012).
  • CONCLUSION: The performed first Bulgarian study on CMT including EFRT and CHT exhibited a certain therapeutic potential in the treatment of HD patients, expressed in the achievement of high long term outcome and low SPM frequency.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Prognosis. Risk Factors. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20192072.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


49. Guadagnolo BA, Punglia RS, Kuntz KM, Mauch PM, Ng AK: Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol; 2006 Sep 1;24(25):4116-22
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.
  • PURPOSE: To estimate the clinical benefits and cost effectiveness of computed tomography (CT) in the follow-up of patients with complete response (CR) after treatment for Hodgkin's disease (HD).
  • PATIENTS AND METHODS: We developed a decision-analytic model to evaluate follow-up strategies for two hypothetical cohorts of 25-year-old patients with stage I-II or stage III-IV HD, treated with doxorubicin, bleomycin, vinblastine, and dacarbazine-based chemotherapy with or without radiation therapy, respectively.
  • With adjustments for quality of life, we found a decrement in quality-adjusted life expectancy for early-stage patients followed with CT compared with non-CT modalities.
  • For advanced-stage patients, annual CT for 5 years is associated with a very small quality-adjusted survival gain over non-CT follow-up with an incremental cost-effectiveness ratio of 9,042,300 dollars/QALY.
  • CONCLUSION: Our analysis suggests that routine CT should not be used in the surveillance of asymptomatic patients in CR after treatment for HD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Decision Support Techniques. Hodgkin Disease / economics. Hodgkin Disease / radiography. Population Surveillance / methods. Tomography, X-Ray Computed / economics
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cost-Benefit Analysis. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Life Expectancy. Markov Chains. Neoplasm Staging. Predictive Value of Tests. Quality-Adjusted Life Years. Sensitivity and Specificity. Survival Analysis. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16943528.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 R25 CA57711-11
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


50. Cutuli B, Borel C, Dhermain F, Magrini SM, Wasserman TH, Bogart JA, Provencio M, de Lafontan B, de la Rochefordiere A, Cellai E, Graic Y, Kerbrat P, Alzieu C, Teissier E, Dilhuydy JM, Mignotte H, Velten M: Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. Radiother Oncol; 2001 Jun;59(3):247-55
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases.
  • PURPOSE: To assess the clinical and histological characteristics of breast cancer (BC) occurring after Hodgkin's disease (HD) and give possible therapies and prevention methods.
  • MATERIALS AND METHODS: In a retrospective multicentric analysis, 117 women and two men treated for HD subsequently developed 133 BCs.
  • The median age at diagnosis of HD was 24 years.
  • The HD stages were stage I in 25 cases (21%), stage II in 70 cases (59%), stage III in 13 cases (11%), stage IV in six cases (5%) and not specified in five cases (4%).
  • Radiotherapy (RT) was used alone in 74 patients (63%) and combined modalities with chemotherapy (CT) was used in 43 patients (37%).
  • Sixteen patients (12%) developed isolated local recurrence.
  • Thirty-nine patients (31.7%) developed metastases and 34 died; 38 are in complete remission whereas five died of intercurrent disease.
  • The 5-year disease-specific survival rate was 65.1%.
  • The 5-year disease-specific survival rates for the pN0, pN1-3 and pN>3 groups were 91, 66 and 15%, respectively (P<0.0001), and 100, 88, and 64% for the TIS, T1 and T2.
  • These secondary BC are of two types: a large number of aggressive tumours with a very unfavourable prognosis (especially in the case of pN>3 and/or T3T4), and many tumours with a 'slow spreading' such as DCIS and microinvasive lesions.
  • These lesions developed especially in patients treated exclusively by RT.
  • CONCLUSIONS: The young women and girls treated for HD should be carefully monitored in the long-term by clinical examination, mammography and ultrasonography.
  • Subsequent mammographies should be performed every 2 years or each year, depending on the characteristics of the breast tissue (e.g. density) and especially in the case of an association with other BC risk factors.
  • This screening seems of importance due to excellent prognosis in our T(1S)T(1) groups, and the possibility of offering these young women a conservative treatment.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / etiology. Breast Neoplasms, Male / etiology. Hodgkin Disease / complications. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Confidence Intervals. Female. Follow-Up Studies. Humans. Italy / epidemiology. Male. Middle Aged. Neoplasm Recurrence, Local / etiology. Prognosis. Retrospective Studies. Risk Factors. Spain / epidemiology. Survival Analysis. Treatment Outcome. United States / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11369065.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Ireland
  •  go-up   go-down


51. Staib L, Gottwald T, Lehnert T, Ruf G, Sturm J, Becker HD, Farthmann E, Herfarth C, Post S, Trede M, Beger HG: Sphincter-saving treatment in epidermoid anal cancer: cooperative analysis of 142 patients in five German university surgical centers. Int J Colorectal Dis; 2000 Nov;15(5-6):282-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sphincter-saving treatment in epidermoid anal cancer: cooperative analysis of 142 patients in five German university surgical centers.
  • Five southern German university centers cooperated in comparing the effect of surgical vs. nonsurgical therapy strategies on survival and sphincter preservation in the treatment of anal cancer.
  • A standardized questionnaire was used to evaluate retrospectively (mean follow-up 30 months) treatment strategy and outcome (survival, colostomy rate, colostomy-free survival) in patients treated between 1987 and 1996.
  • Of the 142 patients 65% had squamous cell, 20% basaloid, 6% adeno-, and 1% undifferentiated carcinoma (8% histology not recorded); 9% were classified in UICC stage I, 37% in stage II, 25% in stage III, and 4% in stage IV (25% not recorded).
  • Primary treatment consisted of local excision (10%), excision plus radio- and/or chemotherapy (17%), radiotherapy (20%), radiochemotherapy (28%), or colostomy with or without resection, radiotherapy, and chemotherapy (23%).
  • We observed no difference between these treatment groups in overall (P = 0.43) or colostomy-free survival (P = 0.14, log-rank).
  • Mean overall survival (in months) was 42 in stage I, 38 in stage II, and 25 in stage III (P = 0.0013); mean colostomy-free survival was 36 in stage I, 26 in stage II, and 16 in stage III (P = 0.0021, log-rank).
  • Outcome was not significantly related to therapeutic strategy (surgery or radio-chemotherapy.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Adenocarcinoma / therapy. Adult. Aged. Aged, 80 and over. Carcinoma / mortality. Carcinoma / surgery. Carcinoma / therapy. Clinical Trials as Topic. Disease-Free Survival. Female. Humans. Male. Middle Aged. Multicenter Studies as Topic. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11151431.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


52. Warady BA, Zobrist RH, Wu J, Finan E, Ferrlecit Pediatric Study Group: Sodium ferric gluconate complex therapy in anemic children on hemodialysis. Pediatr Nephrol; 2005 Sep;20(9):1320-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sodium ferric gluconate complex therapy in anemic children on hemodialysis.
  • Pediatric patients with end-stage renal disease undergoing hemodialysis (HD) frequently develop anemia.
  • In adult patients undergoing HD, intravenous (IV) iron administration is known to replenish iron stores more effectively than oral iron administration.
  • Nevertheless, IV iron supplementation is underutilized in pediatric patients, possibly because of unproved safety in this population.
  • This international, multicenter study investigated the safety and efficacy of two dosing regimens (1.5 mg kg(-1) and 3.0 mg kg(-1)) of sodium ferric gluconate complex (SFGC) therapy, during eight consecutive HD sessions, in iron-deficient pediatric HD patients receiving concomitant rHuEPO therapy.
  • Significant increases from baseline were observed in both treatment groups 2 and 4 weeks after cessation of SFGC dosing for mean hemoglobin, hematocrit, transferrin saturation, serum ferritin, and reticulocyte hemoglobin content.
  • Administration of SFGC was safe and efficacious in the pediatric HD population.
  • Given the equivalent efficacy of the two doses, an initial dosing regimen of 1.5 mg kg(-1) is recommended for pediatric HD patients.
  • [MeSH-major] Anemia, Iron-Deficiency / drug therapy. Ferric Compounds / administration & dosage. Hematinics / administration & dosage. Kidney Failure, Chronic / complications. Renal Dialysis / adverse effects
  • [MeSH-minor] Adolescent. Child. Dose-Response Relationship, Drug. Double-Blind Method. Erythropoietin / therapeutic use. Female. Humans. Infusions, Intravenous. Male. Recombinant Proteins. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pediatr Nephrol. 2005 Dec;20(12):1825
  • [Cites] Nephrol Dial Transplant. 2004 Jan;19(1):141-9 [14671049.001]
  • [Cites] Clin Nephrol. 2003 Feb;59(2):115-23 [12608554.001]
  • [Cites] Pediatr Nephrol. 2000 Sep;14 (10-11):898-902 [10975295.001]
  • [Cites] Pediatr Nephrol. 2004 Jun;19(6):662-6 [15052462.001]
  • [Cites] Am J Kidney Dis. 2000 Jul;36(1):88-97 [10873877.001]
  • [Cites] Am J Kidney Dis. 2001 Jul;38(1):109-17 [11431190.001]
  • [Cites] Pediatr Nephrol. 1991 Nov;5(6):718-23 [1768585.001]
  • [Cites] Semin Nephrol. 1989 Mar;9(1 Suppl 2):25-31 [2669083.001]
  • [Cites] Pediatr Nephrol. 2002 Aug;17(8):656-63 [12185477.001]
  • [Cites] Lancet. 1996 Oct 12;348(9033):992-6 [8855856.001]
  • [Cites] JAMA. 1999 Jun 16;281(23):2225-30 [10376576.001]
  • [Cites] Am J Kidney Dis. 2001 May;37(5):879-83 [11325667.001]
  • [Cites] Pediatr Nephrol. 1990 Nov;4(6):618-22 [2088464.001]
  • [Cites] Am J Kidney Dis. 1999 Mar;33(3):464-70 [10070910.001]
  • [Cites] Am J Kidney Dis. 1999 Mar;33(3):471-82 [10070911.001]
  • [Cites] Pediatr Nephrol. 2004 Jun;19(6):655-61 [15064942.001]
  • [Cites] Kidney Int. 1989 Jan;35(1):134-48 [2651751.001]
  • [Cites] Kidney Int. 1997 Jul;52(1):217-22 [9211366.001]
  • [Cites] Pediatr Nephrol. 2000 Dec;15(3-4):171-5 [11149105.001]
  • [Cites] Am J Kidney Dis. 1998 Feb;31(2):263-72 [9469497.001]
  • [Cites] Clin Nephrol. 1977 Nov;8(5):481-6 [589879.001]
  • [Cites] Pediatr Nephrol. 2003 Oct;18(10):1055-62 [12883982.001]
  • [Cites] Nephrol Dial Transplant. 1995;10(5):607-14 [7566570.001]
  • [Cites] Am J Kidney Dis. 2001 Jan;37(1 Suppl 1):S182-238 [11229970.001]
  • [Cites] Pediatr Nephrol. 2004 Jan;19(1):77-81 [14634860.001]
  • [Cites] Am J Kidney Dis. 1996 Oct;28(4):529-34 [8840942.001]
  • [Cites] Pediatr Nephrol. 2001 Oct;16(10):779-83 [11605781.001]
  • [Cites] Kidney Int. 2002 May;61(5):1830-9 [11967034.001]
  • [Cites] J Am Soc Nephrol. 2002 May;13(5):1288-95 [11961017.001]
  • [Cites] J Clin Invest. 1976 Aug;58(2):447-53 [956378.001]
  • [Cites] ASAIO J. 2002 Jul-Aug;48(4):404-6 [12141472.001]
  • [Cites] Kidney Int. 2001 Dec;60(6):2406-11 [11737617.001]
  • [Cites] Pediatr Nephrol. 2004 Mar;19(3):337-40 [14745634.001]
  • [Cites] Am J Kidney Dis. 1993 Aug;22(2 Suppl 1):3-12 [8352269.001]
  • [Cites] Pediatr Nephrol. 2000 Sep;14(10-11):908-11 [10975297.001]
  • [Cites] Clin Exp Nephrol. 2003 Mar;7(1):52-7 [14586744.001]
  • [Cites] Am J Kidney Dis. 2000 Dec;36(6 Suppl 3):S39-51 [11118157.001]
  • [Cites] Kidney Int. 2004 Jan;65(1):266-73 [14675059.001]
  • [Cites] Pediatr Nephrol. 1999 Sep;13(7):580-2 [10460505.001]
  • (PMID = 15971073.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ferric Compounds; 0 / Hematinics; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; W108RK810P / ferric gluconate
  •  go-up   go-down


53. Cellai E, Magrini SM, Masala G, Alterini R, Costantini AS, Rigacci L, Olmastroni L, Papi MG, Spediacci MA, Innocenti F, Bellesi G, Ferrini PR, Biti G: The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University Hospital. Int J Radiat Oncol Biol Phys; 2001 Apr 1;49(5):1327-37
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University Hospital.
  • PURPOSE: To quantify the incidence of second malignant tumors (SMT) as a whole and that of second "solid" tumors (SST) and leukemia (L) in a large series of 1524 Hodgkin's disease (HD) patients (pts) treated at the Florence University Hospital (UFH); to define the clinical and therapeutic features possibly related with SMT occurrence; to evaluate the consequences of SMT for the overall survival of the series studied and for the choice of the treatment of HD at presentation.
  • METHODS AND MATERIALS: From 1960 to 1991, 1524 pts with HD, Clinical Stage (CS) I--IV have been treated at the UFH.
  • Overall treatment consisted of radiation alone (RT, 36%), chemotherapy alone (CHT, 21%), or both (RT + CHT, 43%).
  • The cumulative probability (CP) of SMT, SST, and L was calculated for the whole series and for the different clinical and therapeutic subgroups, and the results compared with uni- and multivariate analysis ("internal" comparison, IC).
  • Standardized incidence ratios (SIR) for different SMT types (estimated on the basis of gender, age, period specific incidence rates of the general population) have been also calculated ("external" comparison, EC).
  • Both IC and EC showed a statistically significant relationship between L incidence and treatment with CHT, alone or in combination with RT.
  • A significant excess of breast cancers has been observed in RT-treated patients with longer follow-up (SIR, 2.9); an excess of other common SST (lung, non-Hodgkin's lymphomas) is evident in pts treated with either RT, RT + CHT, or CHT.
  • The actuarial long-term survival of the series would have been better of about 3%, in absence of the SMT mortality possibly due to HD treatment, which is almost equally divided between patients treated with RT alone, CHT alone, and RT + CHT.
  • CONCLUSIONS: SMT represent an important late event in HD long-term survivors.
  • The relationship between L and treatment with CHT seems to be the most clearly defined.
  • The effect of SMT on the survival of the entire series, although not negligible, does not seem to justify by itself substantial alterations in the current standards for the treatment of HD at presentation.
  • [MeSH-major] Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Leukemia / epidemiology. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adult. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Confidence Intervals. Female. Humans. Incidence. Male. Mechlorethamine / administration & dosage. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Risk Factors. Sex Factors. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11286841.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; VB0R961HZT / Prednisone; MOPP protocol
  •  go-up   go-down


54. Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I: ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant; 2006 Feb;37(3):277-82
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients.
  • From 1996 to November 2004, 131 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin's lymphoma (HD) received ESHAP as mobilization chemotherapy before autologous peripheral blood stem cell transplant (ASCT).
  • DLCL 49: HD 78.
  • Initial stage I:II:III:IV:unknown was 15:34:33:42:3.
  • Median prior chemotherapy cycles were six [<6 (17 patients), 6-8 (90 patients), >8 (20 patients)].
  • Median total CD34+ cells/kg collected were 6.9 x 10(6) (DLCL 5.17 x 10(6) and HD 7.6 x 10(6)), patients weighing < or = 70 kg (93 patients) 6.54 x 10(6) and >70 kg (34 patients) 7.44 x 10(6) (P = 0.59), one apheresis (93 patients) 8.6 x 10(6)/kg and >1 apheresis (34 patients) 4.5 x 10(6) (P = 0.001).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization. Hodgkin Disease / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Blood Component Removal / methods. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Methylprednisolone / administration & dosage. Recurrence. Retrospective Studies. Transplantation, Autologous

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400345.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


55. Chisesi T, Federico M, Levis A, Deliliers GL, Gobbi PG, Santini G, Luminari S, Linfomi MB, Intergruppo Italiano Linfomi: ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial. Ann Oncol; 2002;13 Suppl 1:102-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial.
  • BACKGROUND: Between January 1996 and April 2000, 355 patients with advanced Hodgkin's disease (HD) (stage II bulky disease, III and IV) were enrolled in a prospective, multicentre, randomised trial aimed at comparing the efficacy of two new promising regimens: Stanford V and MEC hybrid.
  • Radiotherapy was planned at the end of induction therapy on residual masses or on sites of previous bulky lesions.
  • RESULTS: After induction therapy a complete response (CR) was observed in 93, 89 and 74% of patients treated with MEC, ABVD and Stanford V, respectively, with a statistically significant difference (P = 0.013) between the arms.
  • Toxicity was comparable in the three treatment arms.
  • Notwithstanding the short follow-up, these results seem to be very impressive in defining the best standard treatment for HD for this subset of patients.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12078888.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone
  •  go-up   go-down


56. Smith BM, Slade MJ, English J, Graham H, Lüchtenborg M, Sinnett HD, Cross NC, Coombes RC: Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol; 2000 Apr;18(7):1432-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques.
  • PURPOSE: We previously developed a quantitative system for the detection of cytokeratin 19 (CK-19) transcripts using reverse transcriptase polymerase chain reaction (PCR) to detect breast carcinoma cells in blood and bone marrow.
  • The aim of this study was to determine the value of this system in monitoring patients with metastatic disease and to compare it with an established immunocytochemical method.
  • PATIENTS AND METHODS: Patients with progressive, locally advanced, and metastatic breast cancer (all stage IV) who were due to start systemic treatment were recruited.
  • Blood samples were analyzed for CK-19 transcripts using quantitative PCR (QPCR) and immunocytochemistry (ICC) throughout their course of treatment.
  • Of the 25 courses of assessable treatment, 17 (68%) of 25 treatment outcomes (either response or disease progression) were reflected by QPCR measurements, and 12 (57%) of 21 were reflected by ICC.
  • Eighteen courses of treatment resulted in progression of the disease; however, only 15 of these were assessable by ICC.
  • CONCLUSION: Circulating carcinoma cells are frequently found in patients with metastatic breast cancer.
  • In the majority of patients, cancer cell numbers as evaluated by QPCR or ICC reflected the outcome of systemic treatment.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Neoplastic Cells, Circulating / immunology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Predictive Value of Tests. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity


57. Re A, Casari S, Cattaneo C, Facchetti F, Cadeo G, Carosi G, Rossi G: Hodgkin disease developing in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer; 2001 Dec 1;92(11):2739-45
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin disease developing in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus-related non-Hodgkin lymphoma.
  • BACKGROUND: Unlike aggressive non-Hodgkin lymphoma (NHL), Hodgkin disease (HD) develops rarely in patients who are infected by human immunodeficiency virus (HIV), and its characteristics are not well defined.
  • The authors analyzed the clinicopathologic and prognostic features from a consecutive series of patients with HIV-associated HD who were observed at their institution and compared them with the features observed in a concurrent series of patients with systemic HIV-related NHL.
  • Their demographic, immunologic, and clinicopathologic features; responses to treatment; and outcomes were compared with those of 98 patients with systemic NHL of aggressive histology who were diagnosed during the same period and with 165 HIV negative patients with HD.
  • RESULTS: HIV-associated HD and NHL occurred in patients with similar age, gender, HIV risk factors, degree of immunodeficiency, and incidence of previous acquired immunodeficiency syndrome.
  • The clinical presentation of HIV-associated HD was atypical and was more aggressive than in HIV negative patients (mediastinal involvement, 11%; Stage III-IV, 84%; B symptoms, 83%).
  • It was similar to HIV-related NHL, except for the frequency of extralymph node disease, which was seen less frequently in patients who had HD (56%) compared with patients who had NHL (82%; P = 0.025), and the frequency of bone marrow involvement, which was unexpectedly higher in patients who had HD (50%) compared with patients who had NHL (20%; P = 0.011).
  • Potentially curative treatment was administered to 77% of patients with HD and 66% of patients with NHL.
  • Complete remission and disease recurrence rates as well as disease free and overall survival rates did not differ significantly, with estimated overall survival at 5 years of 24% in patients with HD and 23% in patients with NHL.
  • CONCLUSIONS: HIV-associated HD is an aggressive disease with demographic, clinical, and prognostic features nearly identical to those of HIV-related NHL.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. HIV Infections / complications. Hodgkin Disease / etiology
  • [MeSH-minor] Adult. Female. Humans. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy. Male. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome


58. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O'Callaghan M: Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int; 2002 Dec;62(6):1933-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
  • BACKGROUND: Fabry disease, a lysosomal storage disease caused by deficient lysosomal alpha-galactosidase A activity, is characterized by globotriaosylceramide (GL-3) accumulation in multiple cell types, particularly the vasculature, leading to end organ failure.
  • With the advent of recombinant protein synthesis technology, enzyme replacement therapy has become a viable alternative to dialysis or renal transplantation, previously the only available treatment options for end-stage renal disease.
  • METHODS: The pre- and post-treatment renal biopsies were analyzed from fifty-eight Fabry patients enrolled in a Phase 3 double-blind, randomized, placebo-controlled trial followed by a six-month open label extension study of the recombinant human enzyme, alpha-galactosidase A (r-halphaGalA), administered IV at 1 mg/kg biweekly.
  • The purpose of this investigation was to detail the pathologic changes in glycosphingolipid distribution and the pattern of post-treatment clearance in the kidney.
  • RESULTS: Baseline evaluations revealed GL-3 accumulations in nearly all renal cell types including vascular endothelial cells, vascular smooth muscle cells, mesangial cells and interstitial cells, with particularly dense accumulations in podocytes and distal tubular epithelial cells.
  • After 11 months of r-halphaGalA treatment there was complete clearance of glycolipid from the endothelium of all vasculature as well as from the mesangial cells of the glomerulus and interstitial cells of the cortex.
  • Podocytes and distal tubular epithelium also demonstrated evidence for decreased GL-3, although this clearance was more limited than that observed in other cell types.
  • No evidence of immune complex disease was found by immunofluorescence despite circulating anti-r-halphaGalA IgG antibodies.
  • CONCLUSIONS: These findings indicate a striking reversal of renal glycosphingolipid accumulation in the vasculature and in other renal cell types, and suggest that long-term treatment with r-halphaGalA may halt the progression of pathology and prevent renal failure in patients with Fabry disease.
  • [MeSH-major] Fabry Disease / drug therapy. Fabry Disease / metabolism. Trihexosylceramides / metabolism. alpha-Galactosidase / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Antigen-Antibody Complex / analysis. Biopsy. Capillaries / metabolism. Capillaries / pathology. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Epithelial Cells / immunology. Epithelial Cells / metabolism. Epithelial Cells / pathology. Extracellular Matrix / metabolism. Female. Glomerular Mesangium / blood supply. Glomerular Mesangium / immunology. Glomerular Mesangium / pathology. Humans. Male. Muscle, Smooth, Vascular / metabolism. Muscle, Smooth, Vascular / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12427118.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5 MO1 RR00071; United States / NICHD NIH HHS / HD / 5 P30 HD28822; United States / NIDDK NIH HHS / DK / R29 DK 34045
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigen-Antibody Complex; 0 / Trihexosylceramides; 71965-57-6 / globotriaosylceramide; EC 3.2.1.22 / alpha-Galactosidase
  •  go-up   go-down


59. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Cauli A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis; 2010 Jan;69(1):61-4
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To update the follow-up of the Euro-Lupus Nephritis Trial (ELNT), a randomised prospective trial comparing low-dose (LD) and high-dose (HD) intravenous (IV) cyclophosphamide (CY) followed by azathioprine (AZA) as treatment for proliferative lupus nephritis.
  • RESULTS: Death, sustained doubling of serum creatinine and end-stage renal disease rates did not differ between the LD and HD group (5/44 (11%) vs 2/46 (4%), 6/44 (14%) vs 5/46 (11%) and 2/44 (5%) vs 4/46 (9%), respectively) nor did mean serum creatinine, 24 h proteinuria and damage score at last follow-up.
  • Most patients in both groups were still treated with glucocorticoids, other immunosuppressant agents and blood pressure lowering drugs.
  • After 10 years of follow-up, the positive predictive value for a good outcome of an early drop in proteinuria in response to initial immunosuppressive therapy was confirmed.
  • [MeSH-major] Cyclophosphamide / administration & dosage. Immunosuppressive Agents / administration & dosage. Lupus Nephritis / drug therapy
  • [MeSH-minor] Adolescent. Adult. Azathioprine / therapeutic use. Dose-Response Relationship, Drug. Drug Therapy, Combination. Epidemiologic Methods. Female. Humans. Injections, Intravenous. Kidney Function Tests. Male. Middle Aged. Proteinuria / drug therapy. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lupus.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155235.001).
  • [ISSN] 1468-2060
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; MRK240IY2L / Azathioprine
  •  go-up   go-down






Advertisement